

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29

## Single-cell transcriptomic analysis of skeletal muscle regeneration across mouse lifespan identifies altered stem cell states associated with senescence

Lauren D. Walter<sup>1</sup>, Jessica L. Orton<sup>2</sup>, Ern Hwei Hannah Fong<sup>2</sup>, Viviana I. Maymi<sup>3</sup>,  
Brian D. Rudd<sup>1,3</sup>, Jennifer H. Elisseeff<sup>4</sup>, and Benjamin D. Cosgrove<sup>1,2,#</sup>

<sup>1</sup>Genetics, Genomics and Development Graduate Program, <sup>2</sup>Meinig School of Biomedical Engineering, <sup>3</sup>Department of Microbiology & Immunology, Cornell University, Ithaca, NY, USA; <sup>4</sup>Translational Tissue Engineering Center, Wilmer Eye Institute, and Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA

# Contact author: [bdc68@cornell.edu](mailto:bdc68@cornell.edu)

**Abstract:** Skeletal muscle regeneration is driven by the interaction of myogenic and non-myogenic cells. In aging, regeneration is impaired due to dysfunctions of myogenic and non-myogenic cells, but this is not understood comprehensively. We collected an integrated atlas of 273,923 single-cell transcriptomes from muscles of young, old, and geriatric mice (~5, 20, 26 months-old) at six time-points following myotoxin injury. We identified eight cell types, including T and NK cells and macrophage subtypes, that displayed accelerated or delayed response dynamics between ages. Through pseudotime analysis, we observed myogenic cell states and trajectories specific to old and geriatric ages. To explain these age differences, we assessed cellular senescence by scoring experimentally derived and curated gene-lists. This pointed to an elevation of senescent-like subsets specifically within the self-renewing muscle stem cells in aged muscles. This resource provides a holistic portrait of the altered cellular states underlying skeletal muscle regenerative decline across mouse lifespan.

30 **EXTENDED SUMMARY**

31  
32 Skeletal muscle regeneration relies on the orchestrated interaction of myogenic and non-  
33 myogenic cells with spatial and temporal coordination. The regenerative capacity of skeletal  
34 muscle declines with aging due to alterations in myogenic stem/progenitor cell states and  
35 functions, non-myogenic cell contributions, and systemic changes, all of which accrue with age.  
36 A holistic network-level view of the cell-intrinsic and -extrinsic changes influencing muscle  
37 stem/progenitor cell contributions to muscle regeneration across lifespan remains poorly  
38 resolved. To provide a comprehensive atlas of regenerative muscle cell states across mouse  
39 lifespan, we collected a compendium of 273,923 single-cell transcriptomes from hindlimb muscles  
40 of young, old, and geriatric (4-7, 20, and 26 months-old, respectively) mice at six closely sampled  
41 time-points following myotoxin injury. We identified 29 muscle-resident cell types, eight of which  
42 exhibited accelerated or delayed dynamics in their abundances between age groups, including T  
43 and NK cells and multiple macrophage subtypes, suggesting that the age-related decline in  
44 muscle repair may arise from temporal miscoordination of the inflammatory response. We  
45 performed a pseudotime analysis of myogenic cells across the regeneration timespan and found  
46 age-specific myogenic stem/progenitor cell trajectories in old and geriatric muscles. Given the  
47 critical role that cellular senescence plays in limiting cell contributions in aged tissues, we built a  
48 series of tools to bioinformatically identify senescence in these single-cell data and assess their  
49 ability to identify senescence within key myogenic stages. By comparing single-cell senescence  
50 scores to co-expression of hallmark senescence genes *Cdkn2a* and *Cdkn1a*, we found that an  
51 experimentally derived gene-list derived from a muscle foreign body response (FBR) fibrosis  
52 model accurately (receiver-operator curve AUC = 0.82-0.86) identified senescent-like myogenic  
53 cells across mouse ages, injury time-points, and cell-cycle states, in a manner comparable to  
54 curated gene-lists. Further, this scoring approach pinpointed transitory senescence subsets within  
55 the myogenic stem/progenitor cell trajectory that are related to stalled MuSC self-renewal states  
56 across all ages of mice. This new resource of mouse skeletal muscle aging provides a  
57 comprehensive portrait of the changing cellular states and interaction network underlying skeletal  
58 muscle regeneration across mouse lifespan.

## 59 INTRODUCTION

60  
61 Skeletal muscle is heterogeneously composed of interacting immune, stromal, and myogenic cells  
62 that contribute to the maintenance and regeneration of muscle by regulating muscle stem cell  
63 (MuSC) quiescence, proliferation, and differentiation.<sup>1</sup> MuSCs are found between the basal  
64 lamina and the plasma membrane of myofibers and are essential for the initial development of  
65 muscle and in muscle regeneration.<sup>2,3</sup> The MuSC population is maintained across multiple cycles  
66 of growth and regeneration by asymmetrical division which generates additional MuSCs and  
67 *Myod1*+ myoblasts.<sup>2,3</sup> Myoblasts further expand, differentiate, and fuse to form new *Myog*+  
68 myocytes.<sup>2,3</sup> The paired box protein 7 (*Pax7*) transcription factor, predominantly expressed in  
69 MuSCs, regulates the expression of myogenic regulatory factors such as *Myf5* and *Myod1*.<sup>3</sup>

70 During homeostasis, the skeletal muscle microenvironment maintains signals to keep  
71 MuSCs in a non-cycling state and resident mast cells and macrophages monitor for damage.<sup>1,4</sup>  
72 Following muscle injuries, the mature myofibers undergo necrosis and the individual myonuclei  
73 undergo apoptosis.<sup>5,6</sup> Once damage is detected by resident immune cells, inflammatory cells like  
74 neutrophils and macrophages are recruited to the damaged site.<sup>1,2</sup> First, resident macrophages  
75 release *Cxcl1* and *Ccl2*, neutrophil chemoattractants, to signal for neutrophils to invade.<sup>1,4</sup>  
76 Neutrophils reach their maximum abundance in the damaged muscle between 12-24 hours post-  
77 injury, after which they quickly return to basal levels.<sup>4</sup> Resident Cd8+ T cells also respond early  
78 to muscle injury by producing *Ccl2* and recruiting macrophages to the injured muscle.<sup>4</sup> Circulating  
79 monocytes and macrophages enter the muscle environment which is enriched with pro-  
80 inflammatory cytokines that activate macrophages.<sup>1,4</sup> These activated macrophages clear cellular  
81 debris and promote myogenic cell proliferation.<sup>1,5</sup> The active phagocytic macrophages peak in  
82 abundance at 2 days post-injury (dpi) and they are replaced by non-phagocytic macrophages that  
83 peak in abundance at 4-7 dpi.<sup>4</sup> The non-phagocytic macrophages help maintain myogenic cell  
84 differentiation, resolve inflammation, and support the production of connective tissue.<sup>1,4,5</sup> If  
85 macrophages do not clear cellular debris and promote myogenic cell proliferation and  
86 differentiation, the muscle remains inflamed and there are repeated cycles of necrosis and  
87 regeneration.<sup>5</sup> The damaged myofibers are then replaced with adipose tissue, fibrotic tissue, or  
88 bone, instead of new myofibers.<sup>5</sup> A prior study found that there was an increase in the number of  
89 anti-inflammatory macrophages which can contribute to an increase in fibrosis in aged muscle.<sup>7</sup>  
90 It remains controversial how monocytes and macrophages should be classified and whether  
91 broad pro- and anti-inflammatory definitions should be used or whether more varied phenotypic

92 identities better capture their molecular and functional plasticity.<sup>8</sup> In this work, we sought to  
93 distinguish monocyte/macrophage populations by markers and by resident status.

94 Prior studies have found that both CD8+ and CD4+, especially FoxP3+ regulatory T cells,  
95 infiltrate and help repair damaged muscle.<sup>9</sup> In aging, there is a decline in new naive T cells  
96 released from the Thymus.<sup>10</sup> To compensate for this loss, CD4+ T cells in the periphery proliferate  
97 resulting in a shift towards more memory T cell populations throughout aging.<sup>9</sup> Within the memory  
98 T cell population, an increase in senescent and exhausted T cells is observed in aging.<sup>9</sup>

99 In addition to resident immune cells, fibro-adipogenic progenitors (FAPs), bipotent  
100 progenitor cells that can differentiate into fibroblasts and adipocytes, are a part of the skeletal  
101 muscle microenvironment.<sup>1</sup> FAPs are quiescent during homeostasis and activate upon injury.<sup>4</sup>  
102 There is some evidence that in the early stages of injury response FAPs control immune infiltration  
103 and in later stages FAPs control muscle remodeling.<sup>11</sup> They reach peak abundance at 3 dpi and  
104 return to homeostatic levels by 14 dpi.<sup>4</sup> The expansion and decline of FAPs is regulated by  
105 myeloid cells and FAPs that are activated to the fibrogenic phenotype are regulated by anti-  
106 inflammatory macrophages.<sup>4</sup> Fibrogenic FAPs are the primary producers of connective tissue in  
107 injured muscle.<sup>4</sup>

108 Multiple factors that contribute to the reduced functionality of MuSCs in aged tissues have  
109 been reported, including an excess of FAPs and fibroblasts, misbalanced cell division, and the  
110 establishment of senescent MuSCs.<sup>2,4,12,13</sup> Senescence is characterized by a combination of  
111 hallmarks. These include prolonged DNA damage response activation, upregulation of the cell  
112 cycle inhibitors p16<sup>INK4a</sup> (encoded by *Cdkn2a* and referred to as p16 hereafter) and p21<sup>Cip1</sup>  
113 (encoded by *Cdkn1a* and referred to as p21 hereafter) and anti-apoptotic BCL-2 proteins, an  
114 increase in reactive oxygen species levels and of senescence-associated- $\beta$ -galactosidase (SA-  
115  $\beta$ -gal), and a senescence-associated secretory phenotype (SASP).<sup>14</sup> Prior studies have used the  
116 cell cycle proteins p16, p21, p53, and Rb to differentiate between dividing and non-dividing cells,  
117 but the non-dividing cells can include senescent cells and quiescent cells.<sup>15</sup> SA- $\beta$ -gal is also  
118 commonly used to identify senescent cells, but it is also detected in quiescent cells and in stressed  
119 cells.<sup>15</sup> Because these markers are not unique to senescent cells and because senescent cells  
120 are heterogeneous, it has been challenging to identify biomarkers that can accurately and  
121 consistently identify senescent cells.<sup>16</sup>

122 There are extrinsic changes, such as an increase in FAPs, and intrinsic factors, such as  
123 a reduction in asymmetrical self-renewal and an increase in senescent MuSCs, that disrupt  
124 skeletal muscle homeostasis and regeneration in aging.<sup>2</sup> Aged MuSCs exhibit a decline in self-  
125 renewal and ability to differentiate, thus reducing the MuSC pool.<sup>2,4,12,13</sup> Compared to young

126 MuSCs, fewer aged MuSCs are found in quiescence, due to either elevated activation or entering  
127 a pre-senescent state.<sup>12,13</sup> It remains unclear how these extrinsic and intrinsic changes are  
128 integrated systematically and how heterogeneities related to cellular senescence within both  
129 myogenic and non-myogenic cell populations contribute, in part due to a paucity of holistic  
130 analyses of these alterations. Further, it has been posited that temporal and spatial  
131 discoordination between the dynamics in key cell types during the repair process leads to  
132 inefficient outcomes.<sup>2</sup>

133 Single-cell methods have been used previously to understand skeletal muscle  
134 homeostasis and regeneration at various ages.<sup>11,17-32</sup> Recent reports have provided insights into  
135 MuSC dysfunction with aging. A recent human skeletal muscle study observed a decline in the  
136 proportion of MuSCs with age and that *IGFN1*, which is needed for myoblast fusion and  
137 differentiation, is decreased in old (~75 years old) muscle.<sup>28</sup> This report found no difference in  
138 *Cdkn2a* expression by age, but did identify a senescent myonuclei population that expressed  
139 *Cdkn1a* that was more frequent in old than young human samples.<sup>28</sup> A recent study on mouse  
140 skeletal muscle aging based on mass cytometry observed that CD47<sup>hi</sup> MuSCs occur with a higher  
141 frequency in aged mice and exhibit poor regenerative capacity.<sup>33</sup> Another report demonstrated  
142 that quiescent MuSCs in aged mice have reduced expression of Cyclin D1, which is needed for  
143 proper MuSC activation and muscle regeneration.<sup>34</sup>

144 To evaluate the factors that contribute to the age-related decline in skeletal muscle  
145 regeneration in a more comprehensive manner, we have generated a new single-cell RNA  
146 sequencing (scRNA-seq) analysis of uninjured (day 0) and myotoxin-injured (days 1, 2, 3.5, 5,  
147 and 7) tibialis anterior (TA) muscles from young, old, and geriatric mice. We identified a total of  
148 29 cell types, 8 of which had a significant difference in their abundances throughout regeneration  
149 by age. We confirmed changes in age-specific T cell abundance by immunohistochemistry and  
150 flow cytometry. Given the role that cellular senescence plays in limiting cell contributions in aged  
151 tissues, we tested a series of tools to bioinformatically identify senescence in these single-cell  
152 data and found a transfer-learning based scoring approach accurately classified senescent-like  
153 myogenic cells across ages and cell cycling states. This scoring approach revealed that  
154 senescent-like subsets exist at key transitional self-renewal states within the myogenic  
155 stem/progenitor cell pseudotime trajectory across all ages but are elevated in aged muscles. This  
156 resource of mouse skeletal muscle aging provides a more comprehensive portrait of the changing  
157 cellular states underlying skeletal muscle regeneration across mouse lifespan.

## 158 RESULTS

159

160 **Single-cell RNA-sequencing analysis of skeletal muscle regeneration across mouse**  
161 **lifespan.** To comprehensively evaluate skeletal muscle homeostasis and regeneration  
162 throughout aging, we performed single-cell RNA sequencing (scRNA-seq) on 65 mouse skeletal  
163 muscle samples with the 10x Chromium v2 and v3 platforms. Muscle damage was induced in  
164 young (4-7 months-old [mo]), old (20 mo), and geriatric (26 mo) C57BL/6J mice by injecting the  
165 tibialis anterior (TA) muscles with notexin. The injured and uninjured muscles were collected at  
166 six time points (days 0, 1, 2, 3.5, 5, and 7) (**Figure 1A, B**). Together, these 65 scRNA-seq  
167 samples, newly reported here and from our two prior reports<sup>20,35</sup>, contained a total of 365,710 cell  
168 barcodes prior to quality control and filtering (**Supplementary Figure 1A, Extended Data File**  
169 **1**). All samples were processed by aligning sequencing reads to the mm10 mouse reference  
170 genome, removing ambient RNA signatures with SoupX<sup>36</sup>, removing low quality cells, and  
171 identifying and removing doublets with DoubletFinder<sup>37</sup> (**Figure 1C, Supplementary Figure 1**).  
172 The samples were integrated with Harmony<sup>38</sup> to correct for batch effects (**Figure 1C**). The final  
173 dataset contained 273,923 cells. We observed that the cell number was relatively evenly  
174 distributed across the three age groups (**Figure 1D,G**), and within each age group, the number  
175 of cells from each time point was relatively consistent (**Figure 1E**).

176

177 **Multi-step identification of diverse cell types by clustering.** After data integration, shared  
178 nearest neighbor (SNN) clustering was performed, and canonical marker genes were used to  
179 manually identify cell types. The initial clustering resulted in 24 clusters that each received a  
180 unique cell type annotation. Of these, nine were myeloid cell clusters (monocytes, macrophages,  
181 dendritic cells, and neutrophils) that exhibited similar expression profiles. To further clarify the  
182 myeloid cells found in the final dataset, the 9 myeloid cell clusters were subset out, re-clustered,  
183 and re-embedded (**Supplementary Figure 2A-C**). This resulted in 15 clusters that each received  
184 a unique cell type annotation based on known myeloid markers (**Supplementary Figure 2C-D**).  
185 Although this re-clustering did not further clarify the monocyte and macrophage annotations, it did  
186 help to identify more specific dendritic cell and T cell subtypes (**Supplementary Figure 2C-D**).  
187 The dendritic cell and T cell subtype annotations were transferred from the myeloid subset back  
188 to the final dataset based on the cell barcode. The monocyte and macrophage annotations were  
189 not changed based on the myeloid subset. With the additional myeloid subset annotations, we  
190 identified 29 distinct cell types in the final dataset (**Figure 1F, Supplementary Figure 3**).

191 Compared to prior scRNA-seq and snRNA-seq skeletal muscle studies we identified similar broad  
192 cell types and we identified more specific endothelial, FAP, and immune cell subsets.<sup>11,18–30</sup>

193 Lymphoid cell types were 5 of the 17 immune cell clusters. We identified a rare B cell  
194 cluster (0.47% of the final dataset) that expressed *Cd19*, *Cd22*, and *Ms4a1* (**Supplementary**  
195 **Figure 3A**). We identified a natural killer (NK) cell cluster that expressed *Nkg7*, *Gzma*, *Klra4*, and  
196 *Klre1* but, importantly, did not express T cell markers (**Supplementary Figure 3A**). We identified  
197 three T cell clusters all of which expressed *Cd8a* and *Cd8b1*. One of the T cell populations more  
198 strongly expressed *Cd4* while the other two T cell populations expressed *Cd3e*. One of the *Cd3e+*  
199 clusters also strongly expressed the cycling markers *Cdk1* and *Hmgb2* and were thus identified  
200 as cycling *Cd3e+* T cells (**Supplementary Figure 3A**). The other *Cd3e+* T cell population appears  
201 to be non-cycling. The B cells, NK cells, and the non-cycling *Cd3e+* T cells were identified as  
202 unique clusters in the initial clustering of the final dataset. The *Cd4+* and cycling *Cd3e+* T cells  
203 were identified when we subset and re-clustered the myeloid populations (**Supplementary**  
204 **Figures 2C-D and 3A**).

205 Although we incubated the single-cell suspension in erythrocyte lysis buffer, we did see a  
206 small (0.42% of the final dataset) erythrocyte cluster that uniquely and strongly expressed a  
207 variety of hemoglobin genes, including *Hba-a1* and *Hbb-bs* (**Supplementary Figure 3A**).  
208 Erythrocytes are not a native cell type in skeletal muscle, so we have excluded them from the cell  
209 type dynamics analysis.

210 We identified three FAPs populations (adipogenic, pro-remodeling, and stem), a tenocytes  
211 population, and a Schwann and neural/glia cell population. All three of the FAPs populations  
212 expressed *Pdgfra* and *Col3a1* (**Supplementary Figure 3B**). The adipogenic FAPs also  
213 expressed *Adam12*, *Bmb5*, *Myoc*, *Col1a1*, *Dcn*, *Mmp2*, and *Apod*. The pro-remodeling FAPs  
214 uniquely expressed cycling genes like *Cdk1* and *Tyms* in addition to other FAPs markers like  
215 *Tnfrsf10b*, *Il33*, *Adam12*, *Bgn*, and *Hdlbp*. The stem FAPs also expressed *Igfbp5*, *Dpp4*, *Cd34*, *Gsn*,  
216 and *Mmp2*. The tenocyte population expressed some FAPs markers like *Col1a1*, *Dcn*, and *Apod*  
217 and they expressed tenocyte-specific markers *Tnmd* and *Scx*. The Schwann and neural/glia cell  
218 cluster expressed *Ptn* and *Mpz* (**Supplementary Figure 3B**).

219 We identified a pericytes and smooth muscle cells cluster which expressed the pericyte-  
220 specific gene *Rgs5* and *Acta2*, *Myl9*, and *Myh11* (**Supplementary Figure 3C**).<sup>39</sup> Four endothelial  
221 clusters were identified, and they shared strong expression of *Cdh5* and *Pecam1*  
222 (**Supplementary Figure 3C**). The arterial endothelial cells uniquely expressed *Alpl* and *Hey1*, the  
223 capillary endothelial cells strongly expressed *Lpl*, and the venous endothelial cells expressed *Vwf*,  
224 *Hlf1a*, *Icam1*, *Lrg1*, and *Aplnr* (**Supplementary Figure 3C**). The fourth endothelial cluster

225 expressed endothelial markers like *Cdh5* and *Pecam1* and myeloid markers like *S100a8/9*, *Csf1*,  
226 and *Itgam* (**Supplementary Figure 3C**). This cluster was small (0.073% of the final dataset) and  
227 was made up of cells from multiple replicates from the three ages at 0-2 dpi (**Supplementary**  
228 **Figure 5E**). Because this cluster was not unique to a single replicate, or single age, or single time  
229 point, we have maintained it in our analysis.

230

231 **Comparison of cell type dynamics in skeletal muscle regeneration across mouse ages.** For  
232 each time point independent of age, we calculated the percent of cells from each cell type. In  
233 agreement with previous findings, uninjured skeletal muscle (day 0) was mainly composed of  
234 endothelial cells (49.2%), FAPs (20.4%), and myonuclei (15.1%) and there were small  
235 populations of immune cells (2.7%) and MuSCs and progenitors (2.0%) (**Supplementary Figure**  
236 **4A, Supplementary Table 1A**).<sup>20,40</sup> Of the endothelial cells at day 0, the most prominent subtype  
237 were the capillary endothelial cells (42.4%) (**Supplementary Figure 4B, Supplementary Table**  
238 **1B**). The FAPs present at day 0 were mainly adipogenic FAPs (15.6%) (**Supplementary Figure**  
239 **4B, Supplementary Table 1B**). Of the immune cells present at day 0, there were a variety of  
240 monocytes and macrophages (47.2%), B cells (14.6%), non-cycling *Cd3e+* T cells (11.6%),  
241 *Cd209a+* Dendritic cells (10.6%), and Neutrophils (9.3%) (**Supplementary Figure 4D,**  
242 **Supplementary Table 1D**).<sup>40</sup>

243 Following injury (days 1, 2, 3.5, and 5), the most abundant general cell type was the  
244 immune cells (60.9%, 79.7%, 75.2%, 63.2%, respectively) (**Figure 2K, Supplementary Figure**  
245 **4B, Supplementary Table 1B**). As in previous studies<sup>20,40</sup>, non-immune cells like endothelial  
246 cells, FAPs, and myonuclei were present following injury, but at transiently lower relative  
247 abundances. As expected, the most abundant immune cells immediately after injury (day 1) were  
248 neutrophils (32.0%), *Ccr2+* monocytes/macrophages (19.7%), and *Ctsa+* patrolling  
249 monocytes/macrophages (13.7%) (**Supplementary Figure 4C, Supplementary Table 1C**).<sup>20,40</sup>  
250 Immediately following injury (days 1 and 2), there was a more pro-inflammatory environment, as  
251 evident by the abundance of *Ccr2+* monocytes/macrophages. This was followed by a shift at days  
252 3.5 and 5 to a more anti-inflammatory cell population, as evident by the peak in abundance of  
253 *Cx3cr1+* monocytes/macrophages at day 5 (28.7%) (**Supplementary Figure 4C,**  
254 **Supplementary Table 1C**).<sup>20,40</sup> By day 7 the cell type abundances were returning to the  
255 abundances observed at day 0, but there was still a substantial immune cell population (32.1%)  
256 (**Supplementary Figure 4A, Supplementary Table 1A**). The immune population at day 7 mainly  
257 consists of *Cx3cr1+* monocytes/macrophages (24.1%), *Ctsa+* patrolling monocytes/macrophages



258 (13.2%), and non-cycling *Cd3e+* T cells (17.8%) (**Supplementary Figure 4D, Supplementary**  
259 **Table 1D**).

260 We next conducted an analysis of cell-type dynamics across age groups by comparing  
261 the abundance of a given cell type over the entire injury time course. Of the 28 cell types, eight  
262 were identified as having significantly different cell type dynamics across the three ages using a  
263 non-linear modeling approach with multiple hypotheses correction (**Figure 2J, Supplementary**  
264 **Table 2**). In response to injury, we first observed an increase in neutrophils which peaked in  
265 abundance at day 1 and returned to day 0 levels by day 3.5 (**Supplementary Figure 5N**). We  
266 also observed a peak in the abundance of the *Ccr2+* monocytes/macrophages at days 1 and 2  
267 (**Figure 2A**) while the cycling monocytes/macrophages peaked in abundance at day 3.5 (**Figure**  
268 **2D**) and the *Cx3cr1+* monocytes/macrophages peaked in abundance at days 3.5 and 5 (**Figure**  
269 **2C**). We observed two monocyte/macrophage populations, *Mrc1+* and *Ctsa+*  
270 monocytes/macrophages, that responded early to injury (day 2) and remained high through day  
271 5 (**Figure 2B,E**). The geriatric *Mrc1+* monocytes/macrophages maintained a higher abundance  
272 from day 2 to day 7 compared to the young and old cells (**Figure 2B,J**). Additionally, some  
273 lymphoid cell types like NK cells, *Cd3e+* non-cycling T cells, and B cells started to increase in  
274 abundance at day 2, day 3.5, and day 5, respectively (**Figure 2F-H**). We observed a similar  
275 pattern when looking at all three T cell populations combined (**Supplementary Figure 5T**). The  
276 geriatric NK cells did not increase in abundance within the 7-day time course, unlike the young  
277 and old cells (**Figure 2F**).

278 When looking at all three T cell populations combined, we detected very few T cells and  
279 no age-specific differences in abundance at day 0. However, at day 5 we observed a higher  
280 abundance of T cells in old samples, with a significant difference between the old and geriatric  
281 samples (**Figure 2L**; Student's t-test, p-value = 0.01\*). To confirm this, we performed  
282 immunohistochemistry on sectioned TA muscles and observed that CD3+ T cells are detected  
283 more abundantly at day 5 compared to day 0 in the TAs of young, old, and geriatric mice (**Figure**  
284 **2M**). We further used flow cytometry to quantify CD45+CD11c-CD11b-TCR $\beta$ + T cells at days 0  
285 and 5 from dissociated TA muscles of young, old, and geriatric mice (**Figure 2N**). We detected a  
286 low abundance of TCR $\beta$ + T cells out of all CD45+ hematopoietic cells at day 0, but still detected  
287 a significantly higher T cell abundance in old mice compared to young (**Figure 2O**; Student's t-  
288 test, p-value = 0.02\*). Further, we observed an increase in T cell abundance from day 0 to day 5  
289 and a significant difference between the old and young samples at 5 dpi (**Figure 2O**; Student's t-  
290 test, p-value = 0.03\*). Together, these results suggest the abundance of the T cell pool is elevated  
291 specifically in older muscles (20-months of age), but not preserved in geriatric ages.

292 Independent of age, we detected few MuSCs and progenitors immediately following injury  
293 (days 1 and 2; 2.1%, 1.1%, respectively) and the abundance of MuSCs and progenitors peaked  
294 at day 5 (9.7%) (**Supplementary Figure 4A, Supplementary Table 1A**). This was in agreement  
295 with previous studies.<sup>20,40</sup> The peak in MuSCs and progenitors abundance did vary by age with  
296 the young cells peaking at day 5, the old cells peaking at day 3.5, and the geriatric cells peaking  
297 at day 7 (**Figure 2I**). This difference in peak abundance did not result in a statistically significant  
298 difference in the MuSCs and progenitors dynamics by age, but it did demonstrate a delayed  
299 response by the geriatric MuSCs and progenitors. Independent of age, we detected the most  
300 Myonuclei at days 0 and 7 (15.1%, 10.6%, respectively) (**Supplementary Figure 4A,**  
301 **Supplementary Table 1A**). The Myonuclei dynamics were very similar between the three ages,  
302 but we detected more Myonuclei in old and geriatric samples at both days 0 and 7 compared to  
303 young (**Figure 2J, Supplementary Figure 5M**).

304  
305 **Senescence scoring based on single-cell transcriptomic signatures.** Next, we sought to  
306 investigate age-specific differences in senescence within skeletal muscle regeneration. Hallmarks  
307 of mammalian aging include stem cell exhaustion, altered cellular communication, and cellular  
308 senescence.<sup>41</sup> Identifying senescent cells in scRNA-seq data is challenging because the markers  
309 traditionally used to identify senescent cells are either lowly expressed, expressed in select cell  
310 types in single-cell data, and/or assayed in terms of cellular localization and enzymatic function  
311 (**Figure 3A**).<sup>42</sup> For example, senescent cells are commonly identified by persistent expression of  
312 cell cycle regulators p16 (*Cdkn2a*), p21 (*Cdkn1a*), p53, and/or Rb.<sup>15</sup> Senescent cells are also  
313 marked by the senescent associated secretory phenotype (SASP) which includes  
314 proinflammatory cytokines and chemokines, growth modulators, angiogenic factors, and matrix  
315 metalloproteinases (e.g., *Mmp3*).<sup>43</sup> To examine individual gene signatures of senescence, we  
316 quantified the abundance of *Cdkn2a* (encodes p16), *Cdkn1a* (encodes p21), *Mmp3* (a  
317 senescence-associated matrix metalloproteinase), *Glb1* (encodes senescence-associated  $\beta$ -  
318 galactosidase) across all cell types and ages.

319 Expression of these genes depended more on cell type than age, when considering all  
320 time-points and samples together (**Figure 3A**). Given *Cdkn1a*, *Mmp3*, and *Glb1* were widely  
321 expressed across many cell types, we focused on the common senescence hallmark gene  
322 *Cdkn2a*. *Cdkn2a* transcripts were rarely detected, in agreement with previous observations in the  
323 Tabular Muris Senis project<sup>17</sup>, and primarily observed in the MuSCs/progenitors, cycling T cells,  
324 and FAPs. We observed age-associated changes in the relative abundance of *Cdkn2a*+ cells  
325 within any given cell type infrequently significant (**Figure 3B-D**). There was no significant

326 difference in the fraction of *Cdkn2a*<sup>+</sup> MuSCs and progenitors by age or in the fraction of *Cdkn2a*<sup>+</sup>  
327 cycling T cells by age (**Figure 3B-C**). However, we did observe a significant difference in the  
328 fraction of *Cdkn2a*<sup>+</sup> adipogenic FAPs between the young and geriatric ages (**Figure 3D**; Student's  
329 t-test, p-value = 0.03\*).

330 Within the MuSCs and progenitors, we observed an increase in the fraction of cells that  
331 co-expressed *Cdkn2a* and *Cdkn1a* from day 0 to day 3.5, after which it returned to near day 0  
332 levels (**Figure 3E**). Although there was no significant difference by age in the abundance of these  
333 double-positive cells across all timepoints, there was a significant difference at day 3.5 between  
334 the young and old ages (Student's t-test, p-value = 0.03\*) and the young and geriatric ages  
335 (Student's t-test, p-value = 0.01\*) (**Figure 3E-F**). Although *Cdkn2a* and *Cdkn1a* are both cell cycle  
336 inhibitors and senescent markers, their expression was not correlated in MuSCs and progenitors  
337 at day 3.5 on the individual cell level in this dataset, possibly due to transcript detection dropout  
338 (**Figure 3G**). We considered the double-positive *Cdkn2a*<sup>+</sup> and *Cdkn1a*<sup>+</sup> cells as candidate  
339 senescent MuSCs/progenitors and performed Gene Set Enrichment Analysis (GSEA) on day 3.5  
340 at their peak abundance. GSEA found that double-positive MuSCs/progenitors are enriched for  
341 gene-sets associated with muscle weakness and various mitosis-related processes but  
342 diminished in muscle contraction and cytoskeletal processes (**Figure 2H**). Collectively, these  
343 GSEA results suggest that double-positive MuSCs/progenitors have signatures of dysregulated  
344 muscle function and stalled cell cycle-related gene expression.

345 We then used the *Cdkn2a*<sup>+</sup> *Cdkn1a*<sup>+</sup> MuSCs/progenitors as a candidate cell population  
346 to evaluate broader senescence signatures at the single-cell level. We tested two senescence  
347 scoring methods<sup>44,45</sup> and ten senescence-signature (SenSig) gene lists<sup>44,46-49</sup> (**Extended Data**  
348 **File 2**). We refer to the first method as the Two-way Senescence Score (Sen Score) because it  
349 calculates a score based on a list of up- and down-regulated genes. Within this method we tested  
350 six gene lists that were generated from bulk RNA-seq datasets comparing cells with senescence  
351 conditions or markers to control cells from various tissues and cell types.<sup>44,46</sup> We refer to the  
352 second method as the One-way Sen Score because it calculates a score based on a list of up-  
353 regulated genes. Within this method we tested four gene lists, three of which were taken from  
354 gene-ontology databases or curated in other reports.<sup>47-49</sup> We refer to the Methods,  
355 **Supplementary Figure 7**, and **Extended Data File 2** for more details on these two methods and  
356 the gene lists. We note that two of these gene lists are derived from bulk RNA-seq differential  
357 expression analyses of p16<sup>+</sup> and p16<sup>-</sup> cells selected based on transgenic reporter status. One  
358 gene list ("FBR") was generated by Cherry et al from p16<sup>+</sup> versus p16<sup>-</sup> CD29<sup>+</sup> cells isolated from  
359 a foreign body response-driven skeletal muscle fibrosis model in adult *p16-CreER<sup>T2</sup>;Ai14* reporter

360 mice.<sup>44</sup> A second gene list (“Aged Chondrocytes”) was generated from p16+ versus p16–  
361 Aggrecan+ chondrocytes isolated from 20-mo *p16-tdTom;Aggrecan-CreER<sup>T2</sup>;Ai6* mice (B.O.  
362 Diekman, personal communication).<sup>50–52</sup> To compare how the choice of gene list and method  
363 impacted senescence scoring across different cell types, we examined the FBR two-way and one-  
364 way scores in the final scRNA-seq dataset. The Two-way FBR scores were more consistently low  
365 across most cell clusters and exhibited high scores most notably in the FAP and MuSC clusters  
366 (**Figure 3I,K**). The One-way FBR scores had broader distribution, with many more cell types  
367 exhibiting high scores, including FAP, MuSCs, endothelial cell, pericytes and smooth muscle cell,  
368 and monocytes/macrophages clusters (**Figure 3J,L**). Whereas the Two-way FBR scores were  
369 mean-centered around zero from each cell type cluster due to their z-scored counts (**Figure 3K**),  
370 One-way FBR scores had varied cell type averages (**Figure 3L**). These differences complicate  
371 establishing threshold for senescence positivity between cell types in the one-way scores.

372 We established a scoring approach calibrated for sensitivity and specificity in  
373 discriminating *Cdkn2a+* *Cdkn1a+* MuSCs/progenitors across all ages and timepoints and present  
374 the results in receiver-operator curves with performance reported using an area-under-the-curve  
375 (AUC) metric (**Figure 3M-O**). Between the two senescence scoring methods and the ten SenSig  
376 gene sets, the One-way FBR method performed the best of any experimentally derived approach  
377 (AUC = 0.86), and was comparable to the ontology-curated One-way GO: SASP approach (AUC  
378 = 0.88; **Figure 3M-N**). Notably, it performed far better than the recently described SenMayo list  
379 while using the same ssGSEA method (AUC = 0.63). Moreover, the One-way FBR score  
380 accurately discriminated double-positive senescent-like MuSCs across all three ages (AUCs =  
381 0.85-0.88), suggesting it captures common features of senescence irrespective of age (**Figure**  
382 **3O**). We concluded that the One-way FBR method was able to accurately identify senescent-like  
383 cells in a manner that is not biased by a highly curated gene list.

384  
385 **Refined analysis of myogenic subsets.** In the final dataset, we identified two broad myogenic  
386 clusters (**Figure 1F**). We observed a cluster of MuSCs and progenitors that expressed the  
387 myogenic transcription factor *Pax7*<sup>53</sup> and a cluster of myonuclei that expressed *Acta1*, *Myh1*, and  
388 *Myh4*, genes critical for the contractile function of mature skeletal muscle cells<sup>54</sup> (**Supplementary**  
389 **Figure 3C**). We subsetted out these myogenic clusters and re-clustered and re-embedded the  
390 cells, resulting in nine distinct sub-clusters for refined annotation (**Figure 4A-B**). We identified  
391 four progenitor populations that expressed *Pax7*, *Myf5*, *Myod1*, *Myog*, *Mymk*, and *Mymx* and  
392 three myonuclei subtypes (IIX, IIb, IIX/IIb) that expressed *Acta1*, *Ckm*, and *Tnnt3*.<sup>54</sup> We observed  
393 two transcriptomically variant clusters, which expressed both myogenic markers and either

394 endothelial cell markers like *Cd34*, *Cdh5*, and *Pecam1* or monocyte and macrophage markers  
395 like *Ccr2* and *C1qa* (**Supplementary Figure 8**). We suspected these clusters were dominated by  
396 doublets. The first doublet sub-cluster contained cells that co-expressed *Pax7* and *Pecam1*,  
397 suggesting that these were MuSCs/progenitors and endothelial cell doublets (**Supplementary**  
398 **Figure 8A**). The second doublet sub-cluster contained cells that co-expressed *Acta1* and *C1qa*,  
399 suggesting that these were myonuclei and monocyte/macrophage doublets (**Supplementary**  
400 **Figure 8B**). We designated these sub-clusters as ‘Doublets 1’ and ‘Doublets 2’, respectively, and  
401 excluded them from subsequent analyses involving the myogenic subset.

402 The type IIx cluster expressed *Myh1*, the type IIb cluster expressed *Myh4*, and the type  
403 IIx/IIb cluster expressed both *Myh1* and *Myh4* (**Figure 4B, Supplementary Figure 9A-G**).<sup>55</sup> A  
404 previous study also identified a myonuclei cluster that expressed both *Myh1* and *Myh4*, but this  
405 study concluded that this cluster represented cells with high metabolic activity, not cells that  
406 represent a transitional state between types IIx and IIb.<sup>18</sup> We interpret that the type IIx/IIb cluster  
407 identified here represents a transitional state between types IIx and IIb because 39% of the cells  
408 in this cluster co-express *Myh1* and *Myh4* and because this cluster does not differentially express  
409 markers of high metabolic activity (*Tnnc2*, *Tnni2*, *Mb*, *Cox6a2*, *Cox6c*, *Atp5e*, *Atp5g1*)  
410 (**Supplementary Figure 9F-H**).<sup>18,56,57</sup> Additionally, this transitional fiber type is the most common  
411 transitional fiber type in rat and mouse muscle fibers.<sup>58,59</sup> Notably, the type IIx/IIb cluster had a  
412 lower percentage of mitochondrial reads than the type IIx and type IIb clusters, indicating that  
413 these cells were not clustering together due to being lower quality (**Supplementary Figure 9I**).  
414 We did not identify a cluster of neuro-muscular junction or myotendinous junction cells due to a  
415 lack of *Chrme* or *Col22a1* expression (**Supplementary Figure 9H**).<sup>18,29</sup>

416 We then re-embedded the myogenic subset using PHATE<sup>60</sup> and these embeddings were  
417 used by Monocle3<sup>61-63</sup> to organize the cells in pseudotime (**Figure 4B-C**). The pseudotime values  
418 were grouped into 25 bins that contain approximately equal numbers of cells. As the cells  
419 progressed through pseudotime, the order in which myogenic markers were expressed followed  
420 a typical trajectory of myogenesis. Early pseudotime bins had predominant expression of *Pax7*  
421 and *Myf5*, but no strong expression of activation markers (**Supplementary Figure 10A-F**).  
422 Further in the pseudotime progression, cells still expressed *Pax7* and *Myf5*, but they also  
423 expressed cycling markers such as *Cdk1/4*. In later pseudotime bins, cells expressed *Myod1*,  
424 *Myog*, *Mymx*, and *Mymk*, markers of committed and fusing progenitors. In the latest pseudotime  
425 bins, cells expressed *Acta1*, *Ckm*, *Myh1*, and *Myh4*, markers of myogenic maturation.

426

427 **Pseudo-temporal analysis of myogenesis progression across mouse age and injury time.**

428 To directly compare myogenesis in regeneration responses, we assembled an annotated  
429 “cartography” of myogenic progression arrayed across both day post-injury and myogenic  
430 pseudotime. We first examined the percent of cells that fell within each of the 25 initial pseudotime  
431 bins by time-point and age, and then used expression frequency of myogenic marker genes to  
432 inform myogenic cell-state annotations (**Supplementary Figure 10A-H**). Pseudotime bins 1-6  
433 exhibited age-specific cell abundances, with bins 1-2 predominantly containing cells from young  
434 mice, bin 3 from young and old mice, bin 4 contained cells from old mice, bin 5 from old and  
435 geriatric mice, and bin 6 from geriatric mice only. Bins 1-6 cells expressed *Pax7* and *Myf5*, which  
436 we annotated as MuSCs (with sub-stages 1-6 preserved). Bins 7-13 at 0 dpi expressed *Pax7*,  
437 *Myf5*, and *Myod1* and lowly expressed cycling markers *Cdk1* and *Cdk4*, which we annotated as  
438 Non-cycling MPCs. Cells in bin 7 and dpi 1-3.5 and cells in bins 8-11 and dpi 1-7 expressed  
439 *Myod1* and cycling markers *Cdk1* and *Cdk4*, which we annotated as Cycling MPCs. Cells in bin  
440 12 at dpi 0-7 and cells in bin 13 at dpi 1-2 have diminishing expression of *Myf5*, *Cdk1* and *Cdk4*,  
441 and increasing expression of *Myog* and *Mymk*, which we annotated as Committing MPCs. Cells  
442 in pseudotime bin 13 and dpi 3.5-7 highly expressed *Myog* and *Mymk* and lowly expressed *Cdk1*  
443 and *Cdk4*, which we annotated as Fusing Myocytes. Cells in pseudotime bins 14-25 and dpi 0-7  
444 expressed *Acta1*, which we annotated as Myonuclei. These pseudotime-informed myogenic cell  
445 stage aggregates (summarized in **Supplementary Figure 10I**) were used in subsequent  
446 analyses.

447 To infer the cell-cycle phases, we first assigned each myogenic cell S-phase and G2M-  
448 phase scores using Seurat’s standard Cell-Cycling Scoring method<sup>64</sup> (**Figure 4D**). We treated  
449 these scores as polar coordinates, which were converted to cartesian coordinates and normalized  
450 to be within a range from 0 to 1 (“normalized theta”; **Figure 4E-G, Supplementary Figure 11A-**  
451 **B**). We assessed all myogenic cells within this cell cycle progression from a normalized theta of  
452 0 to 1, corresponding to the continuum of G1–S–G2M stages (**Figure 4E, Supplementary Figure**  
453 **11A-B**). When considering all MuSCs/progenitors, the distribution of normalized theta values  
454 increased from day 0 to day 3.5 and nearly returned to day 0 levels by day 7 in all age groups,  
455 suggesting a return to quiescence as expected (**Supplementary Figure 11E**). We observed a  
456 shift to higher normalized theta values at 1 dpi in the geriatric samples compared to the young  
457 and old myogenic cells, suggesting an age-skewed cell-cycle induction in early injury-response  
458 that may represent a precocious activation phenotype. Differences by age group were minimal  
459 after 3.5 dpi. When examining all myogenic cells by the 25 pseudotime bins, we observed a shift  
460 in normalized theta values at bin 7 persisting through bin 13 (**Supplementary Figure 11F**).

461 Notably, pseudotime bins 7-13 also highly expressed the cycling markers *Cdk1* and *Cdk4*  
462 **(Supplementary Figure 10G-H).**

463 We then found that *Cdk1* and *Cdk4* are more highly expressed in cells predicted to be in  
464 S or G2M than in cells predicted to be in G1 **(Figure 4F-G)**. Seurat's standard G1 cutoff is at a  
465 normalized theta value of 0.25. Based on the expression of cycling markers *Cdk1* and *Cdk4* and  
466 the distribution of cells across the normalized theta values, we extended the G1 cutoff to 0.375  
467 for this analysis **(Figure 4F-G, Supplementary Figure 11C-D)**. For simplicity, cells with a  
468 normalized theta below and above 0.375 were classified as "G1" and "Non-G1" (S/G2/M),  
469 respectively **(Supplementary Figure 11C-D)**.

470 We then calculated the percent of cells within each myogenic cell stage and time-point by  
471 age group. Within the MuSC 1-6 stages at 0-1 and 5-7 dpi, we observed high levels of *Pax7*  
472 **(Figure 4H)**. We also detected a high fraction of Non-G1 cells in MuSCs 1-6, especially at 1-3.5  
473 dpi in the old and geriatric mice **(Figure 4K)**. This suggested that more of the old and geriatric  
474 MuSCs were actively cycling post-injury compared to the young MuSCs. We compared the 3.5  
475 dpi cells in the MuSC 1 and MuSC 2-6 stages by differential gene expression and found that the  
476 quiescence-associated genes *Cdkn1c* (encoding p57<sup>Kip2</sup>) and *Socs3* were upregulated in MuSCs  
477 1 and numerous translation-associated genes such as *Rps29* were upregulated in MuSCs 2-6  
478 **(Figure 4L)**. These expression profiles suggest that MuSCs 1 cells are in a less activated state  
479 MuSCs 2-6 cells.

480 We observed an inverse relationship between the average *Myog* expression and the  
481 fraction of Non-G1 cells in the Cycling MPCs, Committing MPCs, and Fusing Myocytes, as  
482 expected for differentiating myogenic cells **(Figure 4I,K)**. In all ages we detected the highest  
483 average expression of *Myog* in the Fusing Myocytes population **(Figure 4I)**. We detected  
484 Myonuclei in all ages and at every dpi, but there were fewer Myonuclei with lower average  
485 expression of *Acta1* at dpi 1-3.5 in the geriatric mice compared to the young and old mice **(Figure**  
486 **4J)**. Together, these results present an integrated cellular cartography of myogenic trajectories  
487 through regeneration, which exhibits age-associated cellular trajectories, particularly within the  
488 MuSC pool.

489  
490 **Scoring cell senescence across the myogenic cell cycle.** To explore how cellular senescence  
491 manifests within this organized cartography of myogenesis, we focused on the One-way FBR Sen  
492 Score which performed well across ages **(Figure 3O)**. To identify cells with senescence-like  
493 identities, we defined a threshold within the One-way FBR Sen Score based on its relationship  
494 with *Cdkn2a* and *Cdkn1a* expression which exhibited correlation **(Supplementary Figure 11G-**

495 **H)**. We set a One-way FBR score threshold at 2412, where 50% of cells above this value co-  
496 expressed *Cdkn2a* and *Cdkn1a*, and classified cells above this threshold as ‘Sen Score high’ and  
497 senescence-like (**Figure 5A**). We further observed through ROC analysis that the One-way FBR  
498 Sen Score could accurately identify double-positive *Cdkn2a* and *Cdkn1a* cells from both the G1  
499 and Non-G1 fractions of MuSCs/progenitors (**Figure 5B**).

500 We aimed to quantify the prevalence of cellular senescence within the cartography of  
501 myogenesis by age using both double-positive expression status and Sen Score, reasoning that  
502 the scores might capture a more expansive set of senescence-like cells. We observed a  
503 correspondence between the fraction of cells that co-express *Cdkn2a* and *Cdkn1a* and the  
504 fraction of cells that have a high Sen Score in most ages, cell stages, and timepoints (**Figure 5C-**  
505 **D**). Focusing on 3.5 dpi, we found a significantly higher fraction of *Cdkn2a*<sup>+</sup> and *Cdkn1a*<sup>+</sup> cells in  
506 both the old and geriatric MuSCs 1 compared to young MuSCs 1 (Student’s t-tests, p-values =  
507 0.02\* and 0.003\*, respectively; **Figure 5E**). We did not observe age-specific differences in the  
508 fraction of *Cdkn2a*<sup>+</sup> and *Cdkn1a*<sup>+</sup> in MuSCs 2-6 (**Figure 5F**). We found a significantly higher  
509 fraction of *Cdkn2a*<sup>+</sup> and *Cdkn1a*<sup>+</sup> in both old and geriatric MPCs (from both Cycling and  
510 Committing stages) compared to young MPCs (Student’s t-tests, p-values = 0.04\* and 0.02\*,  
511 respectively; **Figure 5G**). Likewise, we observed a similar pattern in the fraction of One-way FBR  
512 Sen Score high cells, with significantly higher frequencies in the old compared to young MuSCs  
513 1 (Student’s t-test, p-value = 0.002\*; **Figure 5H**). We did not observe age-specific differences in  
514 the fraction of Sen Score high MuSCs 2-6 or MPCs (**Figure 5I-J**). Together, these observations  
515 point to a transitory senescent-like cell population that is abundant at the self-renewing MuSC 1  
516 stage across all ages, but increases in older mice, potentially underlying a stalled stem-cell self-  
517 renewal in mouse muscle aging.



518 **DISCUSSION**

519

520 We utilized the profiling depth and complexity of scRNA-seq and associated computational  
521 analyses to generate a comprehensive compendium of 273,923 single-cell transcriptomes from  
522 regenerating tibialis anterior muscles throughout mouse lifespan. To date, our dataset is the most  
523 comprehensive portrait of muscle repair at the single-cell level, as it includes three ages (young,  
524 old, and geriatric), six time points (days 0, 1, 2, 3.5, 5, and 7), and includes 29 different cell type  
525 clusters (**Figure 1, Supplementary Figures 1 and 3**). Additionally, compared to previous scRNA-  
526 seq and snRNA-seq skeletal muscle studies, we have identified more specific endothelial, FAPs,  
527 and immune cell sub-types.<sup>11,18–30</sup>

528 The immune, stromal, and myogenic cells found in skeletal muscle contribute to muscle  
529 maintenance and regeneration by regulating MuSC quiescence, proliferation, and differentiation.<sup>1</sup>  
530 It has been shown that an imbalance in immune cell populations during injury response can  
531 disrupt proper muscle repair.<sup>1,2</sup> To investigate this we compared the change in cell type  
532 abundances over our regeneration time course between young, old, and geriatric muscles. As  
533 expected, Neutrophils are one of the first immune cell types to peak in abundance  
534 (**Supplementary Figure 5L**).<sup>4</sup> We also observe monocyte and macrophage populations that  
535 express pro-inflammatory markers like *Ccr2* and patrolling markers like *Ctsa* responding soon  
536 after injury (days 1-2) when we expect the muscle environment to be enriched with pro-  
537 inflammatory cytokines (**Figure 2A,E**).<sup>1,4</sup> Monocytes and macrophages that express pro-  
538 inflammatory markers clear cellular debris and promote myogenic cell proliferation.<sup>1,5</sup> There  
539 should be a shift to monocytes and macrophages that express anti-inflammatory marker *C1qa* at  
540 4-7 dpi (**Figure 2B-C, Supplementary Figure 3A**).<sup>4</sup> We do broadly observe a shift from  
541 monocytes and macrophages that express pro-inflammatory markers to anti-inflammatory  
542 markers, but there are significant differences by age (**Figure 2A-E**). This difference in monocyte  
543 and macrophage dynamics could explain the age-related decline in muscle repair because if  
544 macrophages do not clear cellular debris or promote myogenic cell proliferation and  
545 differentiation, the muscle remains inflamed and there are repeated cycles of necrosis and  
546 regeneration.<sup>5</sup> The damaged myofibers are then replaced with adipose tissue, fibrotic tissue, or  
547 bone, instead of new myofibers.<sup>5</sup>

548 In addition to age-specific differences in the dynamics of the monocyte and macrophage  
549 populations, we observe age specific differences in the T cell dynamics (**Figure 2L-O,**  
550 **Supplementary Figure 5T**). It has previously been shown that Treg cells, marked by *Cd4* and  
551 *Foxp3*, accumulate in injured muscle and to peak in abundance at day 4.<sup>4</sup> We detected *Foxp3*

552 expression in a few T cells, specifically in the T cell (Cycling) and T cell (Non-Cycling) populations  
553 which both highly express *Cd3e* (**Supplementary Figure 3A**). Although we cannot confidently  
554 identify any of our three T cell populations as Tregs, we do observe a peak in T cell abundances  
555 at days 5 and 7 (age-specific). There is miscoordination of T cell response which in turn could  
556 impact the ability of aged muscle to repair itself.

557 One factor that has been shown to contribute to the reduced functionality of MuSCs in  
558 aged tissues is the establishment of senescent MuSCs.<sup>2,13</sup> Prior studies have used the cell cycle  
559 proteins p16, p21, p53, and Rb to differentiate between dividing and non-dividing cells, but the non-  
560 dividing cells can include senescent cells and quiescent cells.<sup>15</sup> SA- $\beta$ -gal is also commonly used to  
561 identify senescent cells, but it is also detected in quiescent cells and in stressed cells.<sup>15,65</sup> Because  
562 these markers are not unique to senescent cells and because senescent cells are heterogeneous,  
563 it has been challenging to identify biomarkers that can accurately and consistently identify  
564 senescent cells across species, tissues, and conditions.<sup>16</sup> Indeed, recent large consortia have  
565 been established to develop new tools to detect and bioinformatically identify senescent cells with  
566 robustness and precision throughout mammalian tissues and lifespans.<sup>66</sup> Given the role that  
567 cellular senescence plays in limiting cell contributions in aged tissues, we tested a series of tools  
568 to bioinformatically identify senescence in these single-cell data and found a transfer-learning  
569 based scoring approach accurately classified senescent-like myogenic cells across ages and cell  
570 cycling states. The approach described here to quantitatively assess various senescence scoring  
571 approaches and reference gene lists in discriminating senescent or senescent-like cells (**Figures**  
572 **3** and **5**) may provide a template for future studies using single-cell data. Notably, here we  
573 concluded that a skeletal muscle FBR gene list more accurately and robustly discriminated  
574 senescent-like *Cdkn2a*<sup>+</sup> and *Cdkn1a*<sup>+</sup> MuSC/progenitors in these muscle regeneration datasets  
575 than did a variety of experimental and curated gene lists, including the recently described  
576 SenMayo list.<sup>47</sup> In particular, at day 3.5 post-injury, we observed a significantly higher fraction of  
577 *Cdkn2a*<sup>+</sup> and *Cdkn1a*<sup>+</sup> cells in the aged and geriatric MuSCs associated with a self-renewing cell  
578 stage (MuSC stage 1; **Figure 5E,G**). Likewise, we observed a similar pattern in the fraction of  
579 One-way FBR Sen Score high cells, with significantly higher frequencies in the old compared to  
580 young MuSCs 1 (**Figure 5H**). These observations point to a transitory senescence-like cell  
581 population that is abundant at the self-renewing MuSC stage across all ages, but increases in  
582 older mice, potentially underlying a stalled stem-cell self-renewal in mouse muscle aging.

583 **METHODS**

584

585 **Mouse muscle injury and single-cell isolation.** Muscle injury was induced in young (4-7  
586 months-old [mo]), old (20 mo), and geriatric (26 mo) C57BL/6J mice (Jackson Laboratory #  
587 000664; NIA Aged Rodent Colonies) by injecting both tibialis anterior (TA) muscles with 10  $\mu$ l of  
588 notexin (10  $\mu$ g/ml; Latoxan, France). The mice were sacrificed, and TA muscles were collected at  
589 0, 1, 2, 3.5, 5, and 7 days post-injury (dpi). Each TA was processed independently to generate  
590 single cell suspensions. At each time point, the young and old replicates are biological replicates,  
591 and the geriatric replicates are two pairs of technical replicates (n = 3-4). Muscles were digested  
592 with 8 mg/ml Collagenase D (Roche, Basel, Switzerland) and 10 U/ml Dispase II (Roche, Basel,  
593 Switzerland) and then manually dissociated to generate cell suspensions. Myofiber debris was  
594 removed by filtering the cell suspensions through a 100  $\mu$ m and then a 40  $\mu$ m filter (Corning  
595 Cellgro # 431752 and # 431750). After filtration, erythrocytes were removed by incubating the cell  
596 suspension in erythrocyte lysis buffer (IBI Scientific # 89135-030).

597

598 **Single-cell RNA-sequencing library preparation.** After digestion, the single-cell suspensions  
599 were washed and resuspended in 0.04% BSA in PBS at a concentration of  $10^6$  cells/ml. A  
600 hemocytometer was used to manually count the cells to determine the concentration of the  
601 suspension. Single-cell RNA-sequencing libraries were prepared using the Chromium Single Cell  
602 3' reagent kit v3 (10x Genomics, Pleasanton, CA) following the manufacturer's protocol.<sup>67</sup> Cells  
603 were diluted into the Chromium Single Cell A Chip to yield a recovery of 6,000 single-cell  
604 transcriptomes with <5% doublet rate. Libraries were sequenced on the NextSeq 500 (Illumina,  
605 San Diego, CA).<sup>68</sup> The sequencing data was aligned to the mouse reference genome (mm10)  
606 using CellRanger v5.0.0 (10x Genomics).<sup>67</sup>

607

608 **Preprocessing and batch correction of single-cell RNA sequencing data.** From the gene  
609 expression matrix, the downstream analysis was carried out in R (v3.6.1). First, ambient RNA  
610 signal was removed using the default SoupX (v1.4.5) workflow (autoEstCounts and adjustCounts;  
611 [github.com/constantAmateur/SoupX](https://github.com/constantAmateur/SoupX)).<sup>36</sup> Samples were then preprocessed using the standard  
612 Seurat (v3.2.3) workflow (NormalizeData, ScaleData, FindVariableFeatures, RunPCA,  
613 FindNeighbors, FindClusters, and RunUMAP; [github.com/satijalab/seurat](https://github.com/satijalab/seurat)).<sup>64</sup> Cells with fewer  
614 than 200 genes, with fewer than 750 UMIs, and more than 25% of unique transcripts derived from  
615 mitochondrial genes were removed. After preprocessing, DoubletFinder (v2.0.3) was used to  
616 identify putative doublets in each dataset.<sup>37</sup> The estimate doublet rate was 5% according to the

617 10x Chromium handbook. The putative doublets were removed from each dataset. Next, the  
618 datasets were merged and then batch-corrected with Harmony  
619 ([github.com/immunogenomics/harmony](https://github.com/immunogenomics/harmony)) (v1.0).<sup>38</sup> Seurat was then used to process the integrated  
620 data. Dimensions accounting for 95% of the total variance were used to generate SNN graphs  
621 (FindNeighbors) and SNN clustering was performed (FindClusters). A clustering resolution of 0.8  
622 was used resulting in 24 initial clusters.

623  
624 **Cell type annotation in single-cell RNA sequencing data.** Cell types were determined by  
625 expression of canonical genes. Each of the 24 initial clusters received a unique cell type  
626 annotation. The nine myeloid clusters were challenging to differentiate between, so these clusters  
627 were subset out (Subset) and re-clustered using a resolution of 0.5 (FindNeighbors, FindClusters)  
628 resulting in 15 initial clusters. More specific myeloid cell type annotations were assigned based  
629 on expression of canonical myeloid genes. This did not help to clarify the monocyte and  
630 macrophage annotations, but it did help to identify more specific dendritic cell and T cell subtypes.  
631 These more specific annotations were transferred from the myeloid subset back to the complete  
632 integrated object based on the cell barcode.

633  
634 **Analysis of cell type dynamics.** We generated a table with the number of cells from each sample  
635 ( $n = 65$ ) in each cell type annotation ( $n = 29$ ). We removed the erythrocytes from this analysis  
636 because they are not a native cell type in skeletal muscle. Next, for each sample, we calculated  
637 the percent of cells in each cell type annotation. The mean and standard deviation were calculated  
638 from each age and time point for every cell type. The solid line is the mean percentage of the  
639 given cell type, the ribbon is the standard deviation around the mean, and the points are the  
640 values from individual replicates. We evaluated whether there was a significant difference in the  
641 cell type dynamics over all six time points using non-linear modeling. The dynamics for each cell  
642 type were fit to some non-linear equation (e.g., quadratic, cubic, quartic) independent and  
643 dependent on age. The type of equation used for each cell type was selected based on the  
644 confidence interval and significance ( $p < 0.05$ ) for the leading coefficient. If the leading coefficient  
645 was significantly different from zero, it was concluded that the leading coefficient was needed. If  
646 the leading coefficient was not significantly different than zero, it was concluded that the leading  
647 coefficient was not needed, and the degree of the equation went down one. No modeling equation  
648 went below the second degree. The null hypothesis predicted that the coefficients of the non-  
649 linear equation were the same across the age groups while the alternative hypothesis predicted  
650 that the coefficients of the non-linear equation were different across the age groups. We

651 conducted a likelihood ratio test to see if the alternative hypothesis fits the data significantly better  
652 than the null hypothesis and we used FDR as the multiple comparison test correction.

653

654 **Muscle immunohistochemical analysis.** Muscle injury was induced in young, old, and geriatric  
655 C57BL/6J mice by injecting both TA muscles with 10  $\mu$ l of notexin (10  $\mu$ g/ml; Latoxan, France).  
656 The mice were sacrificed, and TA muscles were collected at 0 and 5 dpi. The TA muscles were  
657 coated in Tissue-Tek O.C.T. Compound (Sakura Finetek # 4583), snap-frozen in liquid nitrogen  
658 cooled isopentane (Thermo Scientific Chemicals # AA19387AP), and then stored at -80C. Frozen  
659 TA muscles were sectioned with a cryostat transversely at 5  $\mu$ m thickness and section slides were  
660 stored at -20C until stained. Sections were fixed with 4% PFA (Electron Microscopy Sciences #  
661 15710) for 10 minutes, washed with 1X PBS, and blocked with 3% BSA (Rockland  
662 Immunochemicals # RLBSA50) at room temperature for 1 hour. Sections were washed with 1X  
663 PBS and then stained with rat anti-mouse CD3 (eBiosciences # 14-0032-82) at 1:100 dilution in  
664 blocking buffer overnight at 4C. Sections were then washed and stained with Alexa Fluor Plus  
665 750 Phalloidin (Life Technologies # A30105) at 1:500 dilution and goat anti-rat 488 (Invitrogen #  
666 A-11006) at 1:250 dilution in blocking buffer for 1 hour at room temperature protected from light.  
667 Sections were then washed with 1X PBS and stained with 5 mg/mL DAPI (Life Technologies #  
668 D3571) at 1:1000 dilution. Slides were mounted with Glycergel mounting medium (Agilent #  
669 C056330-2) and stored at 4C before imaging. Images were acquired using a Nikon Eclipse Ti-E  
670 microscope (Micro-Video Instruments, Inc.), and were analyzed using NIS Elements 5.11.03  
671 software and ImageJ 2.1.0.

672

673 **Immune cell flow cytometric analysis.** Single cell suspensions of uninjured day 0 and injured  
674 day 5 TAs and gastrocnemius muscles were collected in the same way as the single cell  
675 suspensions for scRNA-seq library preparation. However, the single cells were suspended in 90%  
676 FBS and 10% DMSO and frozen at -80C. When ready to use, the single cell suspensions were  
677 thawed in a 37C water bath and then transferred to 15 mL conical tubes. The cells were washed  
678 with staining buffer (1X PBS + 0.5% BSA + 2 mM EDTA) before being spun at 500g for three  
679 minutes and transferred to a 96 well round bottom plate. Cells were incubated with FC block  
680 (TruStain FcX PLUS (anti-mouse CD16/32), Biolegend # 156604) at 4C for five minutes. Cells  
681 were then washed with staining buffer, spun at 500g for three minutes, and incubated with viability  
682 dye (Fixable viability dye APCe780, eBiosciences # 65-0865-14) and surface antibody (see  
683 antibody table) in BSB (Brilliant Stain Buffer Plus, BD Biosciences # 566385) and staining buffer  
684 for 30 minutes at 4C in the dark. Aliquots of cell samples were counted on a MoxiZ Mini Automated

685 Cell Counter. After incubating we followed the manufacturer's protocol (FOXP3 Transcription  
686 factor fixation/permeabilization kit, eBioscience # 00-5521-00) and cells were washed with  
687 staining buffer, spun, and resuspended in FoxP3 1x perm solution (10x Permeabilization buffer,  
688 Invitrogen # 00-8333-56) and incubated for 30 minutes at 4C in the dark. Cells were washed with  
689 1x perm solution, spun twice, and resuspended in an intracellular antibody stain. Cells were  
690 incubated in intracellular antibody stain for 30 minutes at 4C in the dark. Cells were washed with  
691 1x perm and spun twice before being resuspended in staining buffer and transferred to 40  $\mu$ M  
692 blue capped flow tubes. FMO controls were prepared using a mixture of young, old, and geriatric  
693 uninjured and injured TA and gastrocnemius muscles. Flow cytometry was performed using a  
694 FACSymphony A3 (BD) and data was analyzed in FlowJo 10.5.3. Gates were determined using  
695 FMO controls.

696

### 697 Flow cytometry antibodies

Antibody	Clone	Fluorophore	Manufacturer catalog
CD45	30-F11	PECy7	Invitrogen # 25-0451-82
CD11b	M1/70	BUV395	BD Biosciences # 563553
CD11c	N418	PerCPCy5.5	Invitrogen # 45-0114-82
TCR $\beta$	H57-597	APC	eBiosciences # 17-5961-82
CD19	1D3	BV650	BD Biosciences # 563235

698

699 **Senescence scoring.** We tested two senescence scoring methods along with ten senescence  
700 gene lists (**Extended Data File 2**) to identify senescent-like cells within the scRNA-seq dataset.  
701 The Two-way senescence score was calculated using a transfer-learning method developed by  
702 Cherry et al 2023.<sup>44</sup> For this score, all genes in a cell type cluster (**Figure 1F**) were z-scored. The  
703 provided senescence gene list was split into genes that are up- and down-regulated in p16+ cells.  
704 The scale.data slot, which contains the z-scored counts, was extracted from the full dataset. The  
705 genes that were in the up- and down-regulated gene lists were identified and subset out of the  
706 extracted scale.data matrix. Two scores were calculated, one being the sum of the z-scored  
707 counts of the down-regulated genes multiplied by negative one and the other score being the sum  
708 of the z-scored counts of the up-regulated genes. The overall score is the sum of the down-  
709 regulated gene score and the up-regulated gene score scaled by the length of the gene set. With  
710 this method we tested six gene lists: Stimulation Independent, Replicative, Oncogene, Ion-

711 Radiation Induced, Aged-Chondrocyte, and Two-way foreign body response (FBR). The gene  
712 lists were the result of differential expression analysis of bulk RNA-seq experiments comparing  
713 p16+ to p16- cultured fibroblasts (Stimulation Independent, Replicative, Oncogene, and Ion-  
714 Radiation Induced)<sup>46</sup>, uninjured aged chondrocytes (Aged-Chondrocytes) (B.O. Diekman,  
715 personal communication).<sup>50-52</sup>, and CD29+ cells from a FBR model (Two-way FBR)<sup>44</sup>.

716 The One-way Senescence Score was calculated using Single-Sample GSEA as per Saul  
717 et al., 2022.<sup>47</sup> This method uses the raw counts of genes that are upregulated in p16+ cells. With  
718 this method we tested four gene lists: One-way FBR, SenMayo, GO: Senescence, and GO:  
719 SASP. The One-way FBR gene list contains only the upregulated genes found in the Two-way  
720 FBR gene list.<sup>44</sup> The SenMayo gene list is a literature-curated list of genes commonly used to  
721 identify senescent cells.<sup>47</sup> The GO: Senescence gene list is the GO:  
722 FRIDMAN\_SENESCENCE\_UP<sup>48</sup> gene list and the GO: SASP gene list is the GO:  
723 REACTOME\_SENESCENCE\_ASSOCIATED\_SECRETORY\_PHENOTYPE\_SASP<sup>49</sup> gene list.

724 We evaluated the ability of the two methods and the ten gene lists to accurately identify  
725 senescent-like MuSCs and progenitors by calculating a receiver operator characteristic (ROC)  
726 curve. For each MuSCs and progenitor cell, we evaluated whether it expressed both *Cdkn2a* and  
727 *Cdkn1a*. For each method and gene list, the scores were ranked from highest to lowest and then  
728 grouped into 100 bins with approximately the same number of MuSCs and progenitors. We  
729 evaluated the specificity and the sensitivity in each bin where a true positive expresses both  
730 *Cdkn2a* and *Cdkn1a* and has a high senescent score. This analysis was done for all MuSCs and  
731 progenitors (**Figure 3M-N**), MuSCs and progenitors split by age (**Figure 3O, Supplementary**  
732 **Figure 7A-F**), and MuSCs and progenitors split by G1-Status (**Figure 5B, Supplementary**  
733 **Figure 7G-J**). The area under the curve (AUC) was calculated for each ROC curve (**Figures 3M-**  
734 **O and 5B, Supplementary Figure 7K**).

735 Given that the One-way Senescence Score with the FBR gene list performed the best  
736 (AUC = 0.86), we focused on that for further analyses. We next set a threshold of senescence  
737 based on the One-way FBR. We ranked the MuSCs and progenitors from highest to lowest One-  
738 way FBR Sen Score and then grouped the cells into 100 bins with approximately the same number  
739 of MuSCs and progenitors. Within each bin we calculated the fraction of MuSCs and progenitors  
740 that co-express *Cdkn2a* and *Cdkn1a*. The One-way FBR Sen Score where 50% of the MuSCs  
741 and progenitors with at least that score co-express *Cdkn2a* and *Cdkn1a* was set as the  
742 senescence threshold. For the One-way FBR Sen Score, MuSCs and progenitors with a score  
743  $\geq 2412.562$  were called “senescent-like” while all other cells were called “not senescent-like”  
744 (**Figure 5A, Supplementary Figure 11G-H**).

745

746 **Cell cycle scoring.** To each cell in the final dataset, we assigned an S phase score, a G2M phase  
747 score, and a discrete phase classification (G1/S/G2M) using Seurat's standard Cell-Cycling  
748 Scoring method.<sup>64</sup> We have treated the S phase and G2M phase score as polar coordinates to  
749 help us visualize how cells are progressing through the cell cycle (**Figure 4D**). We have converted  
750 the polar coordinates to cartesian coordinates and normalized the theta values so that they range  
751 from 0 to 1 so that cells in G1 have the lowest theta values followed by cells in S and G2M (**Figure**  
752 **4E, Supplementary Figure 11A-B**). This enables us to see how cells are progressing linearly  
753 through the cell cycle. Seurat's standard cutoff between cells classified as G1 versus cells  
754 classified as S is at the normalized theta value of 0.25. Looking at the distribution of cells across  
755 the normalized theta values as well as the expression of cell cycle markers *Cdk1* and *Cdk4*, we  
756 decided to extend the G1 to S cutoff to 0.375 (**Figure 4E-G, Supplementary Figure 11C-D**).  
757 Cells with a normalized theta value  $\geq 0.375$  are considered Non-G1 (S/G2/M).

758

759 **Myogenic cell subsets.** From the final dataset, the cells with the cell type IDs 'MuSCs and  
760 progenitors' and 'Myonuclei' were subset out and the Seurat workflow was partially re-run  
761 (ScaleData, FindVariableFeatures, RunPCA, FindNeighbors, FindClusters, and RunUMAP).  
762 Dimensions accounting for 95% of the total variance were used to generate SNN graphs  
763 (FindNeighbors) and SNN clustering was performed (FindClusters).<sup>64</sup> A clustering resolution of  
764 0.7 was used resulting in 9 clusters. These 9 clusters were assigned general cell type IDs based  
765 on canonical myogenic markers. Of the 9 clusters, 4 were progenitor subtypes, 3 were myonuclei  
766 subtypes, and 2 were doublets (**Figure 4A**).

767 To more specifically ID the doublet clusters we looked at the co-expression of myogenic  
768 and non-myogenic markers (**Supplementary Figure 8**). Using GetAssayData, we extracted the  
769 log-normalized expression values of *Pax7*, *Pecam1*, *Acta1*, and *C1qa* in each cell in the 9  
770 myogenic clusters. For each of the 9 clusters, we plotted cells by their expression values of *Pax7*  
771 and *Pecam1* and by their expression values of *Acta1* and *C1qa*. A density plot was plotted along  
772 the x- and y-axes using `ggmarginal(type = "density")` (**Supplementary Figure 8**). The two clusters  
773 identified as doublets were excluded from the remaining myogenic subset analyses.

774 To identify the myonuclei clusters more specifically, we looked at the expression of  
775 myonuclei markers, markers of high metabolic activity, and the percent of unique transcripts  
776 derived from mitochondrial genes (**Supplementary Figure 9**). Using GetAssayData, we extracted  
777 the log-normalized expression values of *Myh1* and *Myh4* in each cell in the three myonuclei  
778 clusters. For every cell, as defined by the cell barcode, we determined whether the expression



779 value equaled zero (no expression) or exceeded zero (expression) for both *Myh1* and *Myh4*  
780 independently. For each of the three myonuclei clusters, the fraction of cells that expressed *Myh1*  
781 and *Myh4*, only *Myh1*, only *Myh4*, and neither *Myh1* nor *Myh4* were calculate by dividing the  
782 number of cells that expressed *Myh1* and *Myh4*, only *Myh1*, only *Myh4*, and neither *Myh1* nor  
783 *Myh4* by the total number of cells within each myonuclei cluster (**Supplementary Figure 9D-G**).

784 Harmony embedding values from the dimensions accounting for 95% of the total variance  
785 were used for further dimensional reduction with PHATE, using phateR (v1.0.7) (**Figure 4B-C**).<sup>60</sup>  
786 The PHATE embedding values were used by monocle3 (v1.0.0).<sup>61-63</sup> The normal monocle3  
787 workflow was used (cluster\_cells, estimate\_size\_factors, learngraph, order\_cells) where  
788 L1.sigma = 0.4 and the root cell was in the Progenitor 1 cluster. The pseudotime values for each  
789 cell as defined by monocle3 were transferred from the monocle3 CDS object to the myogenic  
790 cells only Seurat object by cell barcode. The pseudotime values were divided into 25 bins with  
791 approximately equal numbers of cells (1089-1090 cells per bin) (**Figure 4C**).

792 We assigned myogenic cell type IDs based on known myogenic marker expression in  
793 each pseudotime bin and dpi. We visualized this with dot plots where the size of the dot  
794 corresponds to the percent of cells in each pseudotime bin and dpi normalized by the dpi. The  
795 color of the dots corresponds to the average log-normalized expression of a select myogenic  
796 marker in each pseudotime bin and dpi (**Supplementary Figure 10A-H**). Cells in pseudotime bin  
797 1 and dpi 0, 1, 2, 3.5, 5, and 7 were classified as 'MuSCs 1', cells in pseudotime bin 2 and dpi 0,  
798 1, 2, 3.5, 5, and 7 were classified as 'MuSCs 2', cells in pseudotime bin 3 and dpi 0, 1, 2, 3.5, 5,  
799 and 7 were classified as 'MuSCs 3', cells in pseudotime bin 4 and dpi 0, 1, 2, 3.5, 5, and 7 were  
800 classified as 'MuSCs 4', cells in pseudotime bin 5 and dpi 0, 1, 2, 3.5, 5, and 7 were classified as  
801 'MuSCs 5', and cells in pseudotime bin 6 and dpi 0, 1, 2, 3.5, 5, and 7 and cells in pseudotime bin  
802 7 and dpi 5 and 7 were classified as 'MuSCs 6' based on expression of *Pax7* and *Myf5*  
803 (**Supplementary Figure 10A-B,I**). Cells in pseudotime bins 7-13 and dpi 0 were classified as  
804 'Non-Cycling MPCs' based on the expression of *Pax7*, *Myf5*, and *Myod1* and the lack of  
805 expression of cycling markers *Cdk1* and *Cdk4* (**Supplementary Figure 10A-C,G-I**). Cells in  
806 pseudotime bin 7 and dpi 1, 2, and 3.5 and cells in pseudotime bins 8-11 and dpi 1, 2, 3.5, 5, and  
807 7 were classified as 'Cycling MPCs' based on the expression of *Myod1* and cycling markers *Cdk1*  
808 and *Cdk4* (**Supplementary Figure 10C,G-I**). Cells in pseudotime bin 12 and dpi 0, 1, 2, 3.5, 5,  
809 and 7 and cells in pseudotime bin 13 and dpi 1 and 2 were classified as 'Committing MPCs' based  
810 on the low expression of *Myod1*, *Myog*, *Mymk* and the still high expression of cycling markers  
811 *Cdk1* and *Cdk4* (**Supplementary Figure 10C-E,G-I**). Cells in pseudotime bin 13 and dpi 3.5, 5,  
812 and 7 were classified as 'Fusing Myocytes' based on the high expression of *Myog* and *Mymk* and

813 low expression of cycling markers *Cdk1* and *Cdk4* (**Supplementary Figure 10D-E,G-I**). Cells in  
814 pseudotime bins 14-25 and dpi 0, 1, 2, 3.5, 5, and 7 were classified as 'Myonuclei' based on the  
815 expression of *Acta1* (**Supplementary Figure 10F,I**).

816 We focused on dpi 3.5 and compared the cells in MuSCs 1, MuSCs 2-6, and all MPCs  
817 (this includes cells classified as Cycling MPCs and cells classified as Committing MPCs). For  
818 each sample, we calculated the fraction of cells that had log-normalized *Cdkn2a* and *Cdkn1a*  
819 counts greater than 0 (**Figure 5E-G**). Within these same groupings we also calculated the fraction  
820 of cells that had a One-Way FBR score greater than 2412.562 (**Figure 6H-J**). We conducted  
821 unpaired, two-sided Student's t-tests to evaluate whether there was a significant difference  
822 between ages.

823

824 **Differential expression analysis and pre-ranked Gene Set Enrichment Analysis.** For select  
825 comparisons we used Seurat's FindAllMarkers() function to identify genes that were differentially  
826 expressed between groups. In the myogenic subset with all ages at day 3.5, we did this analysis  
827 between the cells in 'MuSCs 1' and the cells in 'MuSCs 2-6' (**Figure 4L**). In the MuSCs and  
828 progenitors with all ages at day 3.5, we did this analysis between cells that co-expressed *Cdkn2a*  
829 and *Cdkn1a* (we refer to these cells as 'Double positive') and all other cells (we refer to these  
830 cells as 'other'). Genes that had an FDR-corrected p-value  $\leq 0.05$  were ranked by average log<sub>2</sub>  
831 fold change and used in a Gene Set Enrichment Analysis (GSEA, v4.1.0). The gene set databases  
832 used included h.all.v2023.1.Hs.symbols.gmt, c2.all.v2023.1.Hs.symbols.gmt,  
833 5.all.v2023.1.Hs.symbols.gmt, and c8.all.v2023.1.Hs.symbols.gmt. Significant GO Terms (FDR  
834 q-value  $\leq 0.25$ ) were ranked by the normalized enrichment score (enrichment scores normalized  
835 by the size of the gene set) (**Figure 3H**).

836

837 **Key resource availability.** A complete list of metadata and GEO accessions for the scRNA-seq  
838 data can be found in **Extended Data File 1**. Previously published scRNA-seq data are deposited  
839 in GEO under accessions GSE143437, GSE159500, and GSE162172. Newly collected scRNA-  
840 seq data from young (4.7 mo; days 1 and 3.5) and geriatric (26 mo) mice are deposited in GEO  
841 under accession GSE232106. Fully processed Seurat objects for the final dataset (**Figure 1**) and  
842 the myogenic subset (**Figures 4 and 5**) will be available for download on Dryad upon publication.  
843 Gene lists used in the Senescence Scoring analysis are compiled in the **Extended Data File 2**.  
844 All newly developed code (Senescence Scoring, Cell Cycle Scoring, Pseudotime Binning) will be  
845 available on Github upon publication.

846 **AUTHOR CONTRIBUTIONS**

847 L.D.W., V.I.M., B.D.R., J.H.E., and B.D.C. designed the study. L.D.W., J.L.O., E.H.H.F., and  
848 V.I.M. carried out the experiments. L.D.W. performed computational analyses. L.D.W. and J.L.O.  
849 analyzed experimental data and prepared figures. B.D.R., J.H.E., and B.D.C. supervised the data  
850 analyses. L.D.W. and B.D.C. wrote the manuscript. All authors provided feedback and comments.

851

852 **ACKNOWLEDGEMENTS**

853 We thank Peter Schweitzer and colleagues in the Genomics Facility (Research Resource  
854 Identifier RRID:SCR\_021727) of the Cornell Biotechnology Resource Center in the Cornell  
855 Institute for Biotechnology for their help in performing single-cell RNA-sequencing experiments.  
856 We thank Lydia Tesfa and colleagues in the Flow Cytometry Facility (RRID:SCR\_021740) of the  
857 Cornell Biotechnology Resource Center for their help in performing flow cytometry experiments.  
858 We thank the Cornell Center for Animal Resources and Education for assisting in animal housing  
859 and care. We thank Andrea De Micheli and Ern Hwei Hannah Fong for helping with mouse  
860 procedures and in generating some single-cell RNA sequencing data. We thank Christopher  
861 Cherry in the Elisseeff research group and other members of the JHU-Mayo-NIH SenNet team  
862 for advice on senescence scoring methods. We thank Brian Diekman and his research group for  
863 generating and providing the chondrocyte gene signature. We thank David McKellar for providing  
864 code via his Github repository and helpful advice. This work was supported by the US National  
865 Institutes of Health (NIH) grants R01AG058630 (to B.D.C.), U54AG07977 (to B.D.C. and J.H.E.),  
866 T32HD057854 (to L.D.W.), F30OD032097 (to V.I.M.), R01AI105265 (to B.D.R.), DP1AR076959  
867 (to J.H.E.). The content is solely the responsibility of the authors and does not necessarily  
868 represent the official views of the NIH. We also acknowledge funding support from the  
869 Bloomberg~Kimmel Institute (to J.H.E.) and Morton Goldberg Professorship (to J.H.E.).

870

871 **COMPETING INTERESTS**

872 J.H.E. was previously a consultant and holds equity in Unity Biotechnology, Aegeria Soft Tissue  
873 and is an advisor for Tessera Therapeutics, HapInScience, Regenity, and Font Bio. All other  
874 authors declare no competing interests.

875 **REFERENCES**

876

- 877 1. Bentzinger, C. F., Wang, Y. X., Dumont, N. A. & Rudnicki, M. A. Cellular dynamics in the  
878 muscle satellite cell niche. *EMBO Rep.* **14**, 1062–1072 (2013).
- 879 2. Blau, H. M., Cosgrove, B. D. & Ho, A. T. V. The central role of muscle stem cells in  
880 regenerative failure with aging. *Nat. Med.* **21**, 854–862 (2015).
- 881 3. Wang, Y. X. & Rudnicki, M. A. Satellite cells, the engines of muscle repair. *Nat. Rev. Mol.*  
882 *Cell Biol.* **13**, 127–133 (2011).
- 883 4. Tidball, J. G. Regulation of muscle growth and regeneration by the immune system. *Nat.*  
884 *Rev. Immunol.* **17**, 165–178 (2017).
- 885 5. Sciorati, C., Rigamonti, E., Manfredi, A. A. & Rovere-Querini, P. Cell death, clearance and  
886 immunity in the skeletal muscle. *Cell Death Differ.* **23**, 927–937 (2016).
- 887 6. Alway, S. E. & Siu, P. M. Nuclear Apoptosis and Sarcopenia. in *Sarcopenia – Age-Related*  
888 *Muscle Wasting and Weakness: Mechanisms and Treatments* (ed. Lynch, G. S.) 173–206  
889 (Springer Netherlands, 2011). doi:10.1007/978-90-481-9713-2\_9.
- 890 7. Wang, Y., Wehling-Henricks, M., Samengo, G. & Tidball, J. G. Increases of M2a  
891 macrophages and fibrosis in aging muscle are influenced by bone marrow aging and  
892 negatively regulated by muscle-derived nitric oxide. *Aging Cell* **14**, 678–688 (2015).
- 893 8. Manneken, J. D. & Currie, P. D. Macrophage-stem cell crosstalk: regulation of the stem cell  
894 niche. *Dev. Camb. Engl.* **150**, dev201510 (2023).
- 895 9. Slaets, H., Fonteyn, L., Eijnde, B. O. & Hellings, N. Train your T cells: How skeletal muscles  
896 and T cells keep each other fit during aging. *Brain. Behav. Immun.* **110**, 237–244 (2023).
- 897 10. Rodriguez, I. J. *et al.* Immunosenescence Study of T Cells: A Systematic Review. *Front.*  
898 *Immunol.* **11**, (2021).
- 899 11. Opreescu, S. N., Yue, F., Qiu, J., Brito, L. F. & Kuang, S. Temporal Dynamics and  
900 Heterogeneity of Cell Populations during Skeletal Muscle Regeneration. *iScience* **23**,  
901 100993 (2020).
- 902 12. Chakkalakal, J. V., Jones, K. M., Basson, M. A. & Brack, A. S. The aged niche disrupts  
903 muscle stem cell quiescence. *Nature* **490**, 355–360 (2012).
- 904 13. Sousa-Victor, P. *et al.* Geriatric muscle stem cells switch reversible quiescence into  
905 senescence. *Nature* **506**, 316–321 (2014).
- 906 14. Di Micco, R., Krizhanovsky, V., Baker, D. & d’Adda di Fagagna, F. Cellular senescence in  
907 ageing: from mechanisms to therapeutic opportunities. *Nat. Rev. Mol. Cell Biol.* **22**, 75–95  
908 (2021).


- 909 15. Matjusaitis, M., Chin, G., Sarnoski, E. A. & Stolzing, A. Biomarkers to identify and isolate  
910 senescent cells. *Ageing Res. Rev.* **29**, 1–12 (2016).
- 911 16. Roy, A. L. *et al.* A Blueprint for Characterizing Senescence. *Cell* **183**, 1143–1146 (2020).
- 912 17. Almanzar, N. *et al.* A single-cell transcriptomic atlas characterizes ageing tissues in the  
913 mouse. *Nature* **583**, 590–595 (2020).
- 914 18. Chemello, F. *et al.* Degenerative and regenerative pathways underlying Duchenne muscular  
915 dystrophy revealed by single-nucleus RNA sequencing. *Proc. Natl. Acad. Sci.* **117**, 29691–  
916 29701 (2020).
- 917 19. Cutler, A. A. *et al.* The regenerating skeletal muscle niche drives satellite cell return to  
918 quiescence. *iScience* **25**, 104444 (2022).
- 919 20. De Micheli, A. J. *et al.* Single-Cell Analysis of the Muscle Stem Cell Hierarchy Identifies  
920 Heterotypic Communication Signals Involved in Skeletal Muscle Regeneration. *Cell Rep.* **30**,  
921 3583-3595.e5 (2020).
- 922 21. Dell’Orso, S. *et al.* Single cell analysis of adult mouse skeletal muscle stem cells in  
923 homeostatic and regenerative conditions. *Dev. Camb. Engl.* **146**, (2019).
- 924 22. Dos Santos, M. *et al.* Single-nucleus RNA-seq and FISH identify coordinated transcriptional  
925 activity in mammalian myofibers. *Nat. Commun.* **11**, 5102 (2020).
- 926 23. Giordani, L. *et al.* High-Dimensional Single-Cell Cartography Reveals Novel Skeletal  
927 Muscle-Resident Cell Populations. *Mol. Cell* **74**, 609-621.e6 (2019).
- 928 24. Jin, R. M., Warunek, J. & Wohlfert, E. A. Chronic infection stunts macrophage heterogeneity  
929 and disrupts immune-mediated myogenesis.  
930 <https://insight.jci.org/articles/view/121549/figure/1> (2018) doi:10.1172/jci.insight.121549.
- 931 25. Kalucka, J. *et al.* Single-Cell Transcriptome Atlas of Murine Endothelial Cells. *Cell* **180**, 764-  
932 779.e20 (2020).
- 933 26. Kimmel, J. C., Hwang, A. B., Scaramozza, A., Marshall, W. F. & Brack, A. S. Aging induces  
934 aberrant state transition kinetics in murine muscle stem cells. *Development* **147**, (2020).
- 935 27. Li, H. *et al.* Muscle-secreted granulocyte colony-stimulating factor functions as metabolic  
936 niche factor ameliorating loss of muscle stem cells in aged mice. *EMBO J.* **38**, e102154  
937 (2019).
- 938 28. Perez, K. *et al.* Single nuclei profiling identifies cell specific markers of skeletal muscle  
939 aging, frailty, and senescence. *Ageing* **14**, 9393–9422 (2022).
- 940 29. Petraný, M. J. *et al.* Single-nucleus RNA-seq identifies transcriptional heterogeneity in  
941 multinucleated skeletal myofibers. *Nat. Commun.* **11**, 6374 (2020).

- 942 30. Stepien, D. M. *et al.* Tuning Macrophage Phenotype to Mitigate Skeletal Muscle Fibrosis. *J.*  
943 *Immunol.* (2020) doi:10.4049/jimmunol.1900814.
- 944 31. Tabula Muris Consortium *et al.* Single-cell transcriptomics of 20 mouse organs creates a  
945 Tabula Muris. *Nature* **562**, 367–372 (2018).
- 946 32. Kimmel, J. C. *et al.* Murine single-cell RNA-seq reveals cell-identity- and tissue-specific  
947 trajectories of aging. *Genome Res.* (2019) doi:10.1101/gr.253880.119.
- 948 33. Porpiglia, E. *et al.* Elevated CD47 is a hallmark of dysfunctional aged muscle stem cells that  
949 can be targeted to augment regeneration. *Cell Stem Cell* **29**, 1653-1668.e8 (2022).
- 950 34. Brett, J. O. *et al.* Exercise rejuvenates quiescent skeletal muscle stem cells in old mice  
951 through restoration of Cyclin D1. *Nat. Metab.* **2**, 307–317 (2020).
- 952 35. McKellar, D. W. *et al.* Large-scale integration of single-cell transcriptomic data captures  
953 transitional progenitor states in mouse skeletal muscle regeneration. *Commun. Biol.* **4**, 1–12  
954 (2021).
- 955 36. Young, M. D. & Behjati, S. SoupX removes ambient RNA contamination from droplet-based  
956 single-cell RNA sequencing data. *GigaScience* **9**, (2020).
- 957 37. McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: Doublet Detection in Single-  
958 Cell RNA Sequencing Data Using Artificial Nearest Neighbors. *Cell Syst.* **8**, 329-337.e4  
959 (2019).
- 960 38. Korsunsky, I. *et al.* Fast, sensitive and accurate integration of single-cell data with Harmony.  
961 *Nat. Methods* **16**, 1289–1296 (2019).
- 962 39. Mitchell, T. S., Bradley, J., Robinson, G. S., Shima, D. T. & Ng, Y.-S. RGS5 expression is a  
963 quantitative measure of pericyte coverage of blood vessels. *Angiogenesis* **11**, 141–151  
964 (2008).
- 965 40. Oprescu, S. N., Yue, F., Qiu, J., Brito, L. F. & Kuang, S. Temporal Dynamics and  
966 Heterogeneity of Cell Populations during Skeletal Muscle Regeneration. *iScience* **23**,  
967 100993 (2020).
- 968 41. López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M. & Kroemer, G. The Hallmarks of  
969 Aging. *Cell* **153**, 1194–1217 (2013).
- 970 42. Lähnemann, D. *et al.* Eleven grand challenges in single-cell data science. *Genome Biol.* **21**,  
971 31 (2020).
- 972 43. Gorgoulis, V. *et al.* Cellular Senescence: Defining a Path Forward. *Cell* **179**, 813–827  
973 (2019).


- 974 44. Cherry, C. *et al.* Transfer learning in a biomaterial fibrosis model identifies in vivo  
975 senescence heterogeneity and contributions to vascularization and matrix production across  
976 species and diverse pathologies. *GeroScience* (2023) doi:10.1007/s11357-023-00785-7.
- 977 45. Borcherding, N. *et al.* Mapping the immune environment in clear cell renal carcinoma by  
978 single-cell genomics. *Commun. Biol.* **4**, 1–11 (2021).
- 979 46. Hernandez-Segura, A. *et al.* Unmasking Transcriptional Heterogeneity in Senescent Cells.  
980 *Curr. Biol. CB* **27**, 2652-2660.e4 (2017).
- 981 47. Saul, D. *et al.* A new gene set identifies senescent cells and predicts senescence-  
982 associated pathways across tissues. *Nat. Commun.* **13**, 4827 (2022).
- 983 48. Fridman, A. L. & Tainsky, M. A. Critical pathways in cellular senescence and immortalization  
984 revealed by gene expression profiling. *Oncogene* **27**, 5975–5987 (2008).
- 985 49. Reactome | Senescence-Associated Secretory Phenotype (SASP).  
986 <https://www.reactome.org/content/detail/R-HSA-2559582>.
- 987 50. Henry, S. P. *et al.* Generation of aggrecan-CreERT2 knockin mice for inducible Cre activity  
988 in adult cartilage. *Genes. N. Y. N* **2000** **47**, 805–814 (2009).
- 989 51. Liu, J.-Y. *et al.* Cells exhibiting strong p16INK4a promoter activation in vivo display features  
990 of senescence. *Proc. Natl. Acad. Sci.* **116**, 2603–2611 (2019).
- 991 52. Sessions, G. A. *et al.* Controlled induction and targeted elimination of p16INK4a-expressing  
992 chondrocytes in cartilage explant culture. *FASEB J.* **33**, 12364–12373 (2019).
- 993 53. Wang, Y. X. & Rudnicki, M. A. Satellite cells, the engines of muscle repair. *Nat. Rev. Mol.*  
994 *Cell Biol.* **13**, 127–133 (2011).
- 995 54. Lyons, G. E., Ontell, M., Cox, R., Sassoon, D. & Buckingham, M. The expression of myosin  
996 genes in developing skeletal muscle in the mouse embryo. *J. Cell Biol.* **111**, 1465–1476  
997 (1990).
- 998 55. Schiaffino, S. & Reggiani, C. Fiber types in mammalian skeletal muscles. *Physiol. Rev.* **91**,  
999 1447–1531 (2011).
- 1000 56. Pette, D. & Staron, R. The Molecular Diversity of Mammalian Muscle Fibers. *Physiology* **8**,  
1001 153–157 (1993).
- 1002 57. Pette, D. & Staron, R. S. Myosin isoforms, muscle fiber types, and transitions. *Microsc. Res.*  
1003 *Tech.* **50**, 500–509 (2000).
- 1004 58. Caiozzo, V. J. *et al.* Single-fiber myosin heavy chain polymorphism: how many patterns and  
1005 what proportions? *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **285**, R570-580 (2003).

- 1006 59. Glaser, B. W., You, G., Zhang, M. & Medler, S. Relative proportions of hybrid fibres are  
1007 unaffected by 6 weeks of running exercise in mouse skeletal muscles. *Exp. Physiol.* **95**,  
1008 211–221 (2010).
- 1009 60. Moon, K. R. *et al.* Visualizing structure and transitions in high-dimensional biological data.  
1010 *Nat. Biotechnol.* **37**, 1482–1492 (2019).
- 1011 61. Trapnell, C. *et al.* The dynamics and regulators of cell fate decisions are revealed by  
1012 pseudotemporal ordering of single cells. *Nat. Biotechnol.* **32**, 381–386 (2014).
- 1013 62. Qiu, X. *et al.* Reversed graph embedding resolves complex single-cell trajectories. *Nat.*  
1014 *Methods* **14**, 979–982 (2017).
- 1015 63. Cao, J. *et al.* The single-cell transcriptional landscape of mammalian organogenesis. *Nature*  
1016 **566**, 496–502 (2019).
- 1017 64. Stuart, T. *et al.* Comprehensive Integration of Single-Cell Data. *Cell* **177**, 1888-1902.e21  
1018 (2019).
- 1019 65. Cosgrove, B. D. *et al.* Rejuvenation of the muscle stem cell population restores strength to  
1020 injured aged muscles. *Nat. Med.* **20**, 255–264 (2014).
- 1021 66. Lee, P. J. *et al.* NIH SenNet Consortium to map senescent cells throughout the human  
1022 lifespan to understand physiological health. *Nat. Aging* **2**, 1090–1100 (2022).
- 1023 67. 10x Genomics: Resolving Biology to Advance Human Health. *10x Genomics*  
1024 <https://www.10xgenomics.com/> (2020).
- 1025 68. Illumina | Sequencing and array-based solutions for genetic research.  
1026 <https://www.illumina.com/> (2020).







1028 **Figure 1: Assembly of scRNA-seq atlas of skeletal muscle regeneration across mouse**  
1029 **aging. (A-B)** Overview of experimental design. 3' scRNA-seq (10X Chromium v2 and v3) was  
1030 performed on dissociated tibialis anterior (TA) muscles from young (4-7 mo), old (20 mo), and  
1031 geriatric (26 mo) mice (both sexes) 0-7 days post-notexin injury (dpi) with n = 3-4 replicates per  
1032 age and dpi **(B)**. **(C)** Processing workflow. Each scRNA-seq sample was aligned to the mm10  
1033 mouse reference genome, ambient RNA was removed by SoupX, low quality cells were identified  
1034 and removed, and doublets were identified and removed. All samples were then integrated with  
1035 Harmony, resulting in a final dataset containing 273,923 cells from 65 samples. See  
1036 **Supplementary Figure 1** and **Extended Data File 1** for additional detail. **(D)** Fraction of cells  
1037 from each age group. **(E)** Fraction of cells from each dpi within each age group. **(F-G)** UMAP  
1038 representations of the final dataset. Cells colored by manually assigned cell type IDs based on  
1039 the expression of hallmark skeletal muscle genes (see **Supplementary Figures 2** and **3**) **(F)**.  
1040 Cells are colored by age group, with all other cells in gray **(G)**.



1042 **Figure 2: Age-related changes to cell dynamics during skeletal muscle regeneration. (A-I)**  
1043 Line plots showing cell type relative abundance as a fraction of total cells from 0-7 days post injury  
1044 (dpi). For each sample, the number of cells of the reported type was divided by the total number  
1045 of cells (excluding erythrocytes). Points are each sample (n = 3-4). Ribbon is the standard  
1046 deviation. Statistical significance of age-specific cell type dynamics was evaluated using non-  
1047 linear modeling and FDR-corrected p-values are reported (see **Supplementary Figure 6**). **(J)**  
1048 Statistical significance of age-specific cell type dynamics differences as reported by FDR-  
1049 corrected p-values from non-linear modeling (see **Supplementary Figure 6**). Red line denotes  
1050 the FDR-adjusted p = 0.05 threshold. **(K)** Stacked bar plot of the fraction of cell types across all  
1051 dpis. All 17 immune cell clusters were grouped into a unified "Immune cells (17 CTs)" cluster,  
1052 which is separated out in **Supplementary Figure 4**. **(L)** Scatter plots of the fraction of all T cells  
1053 (3 CTs) at 0 and 5 dpi from the scRNA-seq data. For each sample, the number of all T cells (3  
1054 CTs) was divided by the total number of cells (excluding erythrocytes). Points are each sample  
1055 (n = 3-4). Line is the mean for each age group. Significance was evaluated using the Student's t-  
1056 test. **(M)** Immunohistochemical analysis of CD3+ T cells (green) at day 0 and day 5 post-injury in  
1057 tibialis anterior (TA) muscles from young (5 mo), old (20 mo), and geriatric (26 mo) mice with  
1058 DAPI (blue) as a nuclear counterstain and Phalloidin-750 (pink) as myofiber counterstain. Scale  
1059 bar, 50  $\mu$ m. Arrow denotes CD3+ T cell. **(N)** Flow cytometric analysis of TCR $\beta$ + T cells. After  
1060 gating single viable cells by FSC/SSC and a fixable viability dye (not shown), CD45+  
1061 hematopoietic cells, CD11b- CD11c- non-myeloid cells, and TCR $\beta$ + CD19- T cells were gated  
1062 sequentially. **(O)** Scatter plots of the fraction of TCR $\beta$ + cells out of all CD45+ cells at 0 and 5 dpi.  
1063 Points are each sample (n = 2-7). Line is the mean for each age group. Significance was evaluated  
1064 using the Student's t-test.




1066 **Figure 3: Identification of senescent-like cells using an informatic scoring approach. (A)**  
1067 Dot plot showing the expression frequency and average expression level of select senescence-  
1068 associated genes by cell type and age (across all time-points). **(B-D)** Scatter plots of the fraction  
1069 of *Cdkn2a*<sup>+</sup> cells within the MuSCs and progenitors **(B)**, T cells (Cycling; *Cd3e*<sup>+</sup>) **(C)**, and FAPs  
1070 (Adipogenic) **(D)** across all samples within each age group (n = 20-24). Points are the fraction for  
1071 each sample. Horizontal line is the median for each age group. Significance was evaluated using  
1072 the Student's t-test. **(E)** Line plot of the fraction of MuSCs and progenitors that co-express *Cdkn2a*  
1073 and *Cdkn1a* from 0-7 days post injury (dpi). Points are the fraction for each sample (n = 4). Ribbon  
1074 is the standard deviation. Statistical significance of age-specific dynamics was evaluated using  
1075 non-linear modeling and the FDR-corrected p-values is reported. **(F)** Scatter plot of the fraction of  
1076 MuSCs and progenitors at 3.5 dpi that co-express *Cdkn2a* and *Cdkn1a* by age. Points are the  
1077 fraction for each sample (n = 4). Horizontal line is the median for each age group. Significance  
1078 was evaluated using the Student's t-test. **(G)** Scatter plot of the normalized expression level of  
1079 *Cdkn2a* and *Cdkn1a* transcripts in all individual MuSCs and progenitors at 3.5 dpi. The density is  
1080 shown on the top and to the right of the plot. Blue line represents the linear trend. Ribbon is the  
1081 confidence interval. The inset contains the Pearson correlation coefficient and its statistical  
1082 significance. **(H)** Significantly up- or down-regulated gene ontology terms between *Cdkn2a*<sup>+</sup> and  
1083 *Cdkn1a*<sup>+</sup> (Double Positive) and all other (Other) MuSCs and progenitors at day 3.5. The  
1084 normalized enrichment score and the FDR-corrected q-values were obtained from gene set  
1085 enrichment analysis (GSEA). **(I-J)** Feature plots of the final dataset with the cells colored by the  
1086 re-scaled Two-way FBR senescence score **(I)** and the re-scaled One-way FBR senescence score  
1087 **(J)**. The cells are randomly plotted. **(K-L)** Violin plots of the Two-way **(K)** and One-way **(L)** FBR  
1088 senescence scores in select cell types. **(M-O)** Receiver Operator Characteristic (ROC) curves  
1089 based on the co-expression of *Cdkn2a* and *Cdkn1a* for the six Two-way senescence scores **(M)**,  
1090 the four One-way senescence scores **(N)**, and for each age group using the One-way FBR  
1091 senescence score **(O)**. The area under the curve (AUC) is reported for each ROC curve.



1093 **Figure 4: Age-specific trajectories through myogenesis following injury. (A-C)** Pseudotime  
1094 organization of the myogenic cell subset after re-clustering. Myogenic cells were re-embedded  
1095 with UMAP **(A)** and with PHATE **(B)** and are colored by general myogenic IDs. PHATE  
1096 embeddings were used by Monocle3 to organize the cells in pseudotime where the earliest  
1097 pseudotime is in the upper left corner and the latest pseudotime in the upper right corner.  
1098 Myogenic cells were organized into 25 approximately equal bins of increasing pseudotime values  
1099 **(C)**. **(D)** Each cell was assigned an S phase score and a G2M phase score using Seurat's Cell  
1100 Cycle Scoring method. Scatter plot of the two scores with the cells colored by the predicted cell  
1101 cycle phase based on the two scores. **(E-G)** Polar coordinates (in **D**) were converted to cartesian  
1102 coordinates and rescaled to fit in a range from 0 to 1. Cells are colored by the predicted cell cycle  
1103 phase based on the two scores **(E)** and by the log-normalized expression of *Cdk1* **(F)** and *Cdk4*  
1104 **(G)**. **(H-K)** Dot plots of the average log-normalized expression of *Pax7* **(H)**, *Myod1* **(I)**, and *Acta1*  
1105 **(J)** and by the fraction of non-G1 (S, G2, and M) cells **(K)** in each day post injury (dpi) and  
1106 pseudotime-based myogenic cell state bin. The size of the circle is the percent of cells in each  
1107 pseudotime-based myogenic cell state bin for each age and dpi combination. **(L)** Top 40  
1108 differentially up- and down-regulated genes between cells in MuSCs 1 and MuSCs 2-6 at day  
1109 3.5. All genes highlighted here have an FDR-corrected q-value < 0.05.






1111


1112

1113 **Figure 5: Aging-associated accumulation of senescent-like cells at critical transitory**  
1114 **myogenic cell states. (A)** Scatter plot of the normalized cartesian coordinate Cell Cycle Scores  
1115 and the One-way FBR senescence score in all MuSCs and progenitors. Cells colored in red co-  
1116 express *Cdkn2a* and *Cdkn1a*. All other cells in gray. The vertical line is the G1 cutoff, and the  
1117 horizontal line is where 50% of the cells above this line co-express *Cdkn2a* and *Cdkn1a*. **(B)**  
1118 Receiver Operator Characteristic (ROC) curves based on the co-expression of *Cdkn2a* and  
1119 *Cdkn1a* in the MuSCs and progenitors (all ages and days post-injury (dpi)) in G1 and non-G1 (S,  
1120 G2, and M) when using the One-way FBR senescence score. Area under the curve is reported  
1121 for each ROC curve. **(C-D)** Dot plots of the fraction of cells that co-express *Cdkn2a* and *Cdkn1a*  
1122 **(C)** and the fraction of One-way FBR senescence score-high cells **(D)** in each dpi and pseudotime-  
1123 based myogenic cell state bin. The size of the circle is the percent of cells in each pseudotime-  
1124 based myogenic cell state bin for each age and dpi combination. **(E-G)** Scatter plot of the fraction  
1125 of MuSCs 1 **(E)**, MuSCs 2-6 **(F)**, and all MPCs **(G)** at 3.5 dpi that co-express *Cdkn2a* and *Cdkn1a*  
1126 by age. Points are the fraction for each sample (n = 2-4) and the horizontal line is the median for  
1127 each age group. Significance was evaluated using the Student's t-test. **(H-J)** Scatter plot of the  
1128 fraction of MuSCs 1 **(H)**, MuSCs 2-6 **(I)**, and all MPCs **(J)** at 3.5 dpi that are One-way FBR  
1129 senescence score high by age. Points are the fraction for each sample (n = 2-4) and the horizontal  
1130 line is the median for each age group. Significance was evaluated using the Student's t-test.




1132 **Supplemental Figure 1: Evaluating sample quality. (A-C)** Quality control workflow and  
1133 resulting UMAPs with cells colored by manually assigned cell type IDs based on the expression  
1134 of hallmark skeletal muscle genes. Prior to any quality-control there were 365,710 cells and 24  
1135 cell types were identified, including 6 low-quality (LQ) clusters **(A)**. After ambient RNA removal  
1136 with SoupX, 23 cell types were identified, including 5 LQ clusters **(B)**. After ambient RNA removal  
1137 with SoupX and removal of LQ cells based on the number of genes and UMIs and the percent of  
1138 mitochondrial reads, there were 286,273 cells and 24 cell types were identified, including two  
1139 doublet clusters **(C)**. **(D)** This is the same UMAP as in **(B)**, but the cells are colored by quality  
1140 status. Cells that had <200 genes, <750 UMIs, and >25% mitochondrial reads are considered LQ.  
1141 All other cells are considered high-quality (HQ). **(E)** This is the same UMAP as in **(C)**, but the cells  
1142 are colored by doublet status as determined by DoubletFinder using an estimated doublet rate of  
1143 5%. **(F)** For every cell type cluster in **(C)**, the fraction of singlets and doublets was calculated. **(G-**  
1144 **I)** Violin plots of the number of genes **(G)**, the number of UMIs **(H)**, and the percent of  
1145 mitochondrial reads **(I)** in each sample.


A




B



C




D




1147 **Supplemental Figure 2: Identifying additional immune cell types when focusing on just the**  
1148 **myeloid cells.** (A) Workflow to clarify the myeloid cell types. The 9 myeloid clusters based on  
1149 broad cell type IDs were subset from the final dataset, re-clustered, and re-embedded. More  
1150 specific cell type IDs were manually assigned using genes known to mark myeloid cell types.  
1151 Some of these more specific cell type IDs from the myeloid subset were transferred back to the  
1152 final dataset (**Figure 1F**) based on the cell barcodes. (**B-C**) UMAPs of the myeloid subset after  
1153 re-embedding, the cells are colored by the broad cell type IDs originally identified in the final  
1154 dataset (**B**). After re-clustering, re-embedding, and re-annotating based on known immune cell  
1155 markers, the cells are colored by the more specific cell type IDs (**C**). If the same cell type is in (**B**)  
1156 and (**C**), it has the same color designation in both UMAPs. (**D**) Dot plot showing the expression  
1157 frequency and magnitude of genes used to manually assign the more specific cell type IDs as  
1158 shown in (**C**).






1164 **Supplemental Figure 4: Determining the cell type composition in each day post injury. (A-**  
 1165 **B)** Stacked bar plots of the percent of each cell type found at a given day post injury (dpi). The  
 1166 three endothelial populations were combined into “Endo (3 CTs)”, the three FAPs populations  
 1167 were combined into “FAPs (3 CTs)”, and the 17 immune populations were combined into “Immune  
 1168 cells (17 CTs)” (A). Only the 17 immune populations are combined into “Immune cells (17 CTs)”  
 1169 (this plot is the same as in **Figure 2K**) (B). (C-D) Stacked bar plots of the percent of each immune  
 1170 cell type out of all immune cells at a given dpi. The four dendritic cell populations were combined  
 1171 into “Dendritic cells (4 CTs)” and the three T cell populations were combined into “T cells (3 CTs)”  
 1172 (C). All individual immune cell type IDs (D).






1174 **Supplemental Figure 5: Cell type dynamics (those that are not in main Figure 2).** (A-T) Line  
1175 plots for the remaining cell types not shown in **Figure 2** showing cell type relative abundance as  
1176 a fraction of total cells from 0-7 days post injury (dpi). For each sample, the number of cells of the  
1177 reported type was divided by the total number of cells (excluding erythrocytes). Points are each  
1178 sample (n = 3-4). Ribbon is the standard deviation. Statistical significance of age-specific cell type  
1179 dynamics was evaluated using non-linear modeling and FDR-corrected p-values are reported  
1180 (see **Supplementary Figure 6**).

1181A




1182


1183 **Supplemental Figure 6: Cell type dynamics non-linear modeling. (A-B)** Plots of the fraction  
1184 of MuSCs and progenitors from 0-7 days post injury (dpi) by age. For each sample, the number  
1185 of cells was divided by the total number of cells (excluding erythrocytes). The points are the  
1186 fraction for each sample (n = 3-4) and the ribbon is the confidence interval. The black line is the  
1187 non-linear model independent of age (**A**) and the three colored lines are the non-linear model  
1188 dependent on age (**B**). Whether there was a significant difference in the non-linear models  
1189 independent of and dependent on age was determined using a likelihood ratio test (ANOVA) and  
1190 the p-values were corrected with FDR. (**C-D**) Same as in (**A-B**) but with NK cells.



1192 **Supplemental Figure 7: Evaluation of accuracy of senescence scoring methods. (A-F)**  
1193 Receiver Operator Characteristic (ROC) curves based on the co-expression of *Cdkn2a* and  
1194 *Cdkn1a* for the six Two-way senescence scores (**A-C**) and the four One-way senescence scores  
1195 (**D-F**) split into young (**A, D**), old (**B, E**), and geriatric (**C, F**) MuSCs and progenitors. (**G-J**) ROC  
1196 curves based on the co-expression of *Cdkn2a* and *Cdkn1a* for the six Two-way senescence  
1197 scores (**G-H**) and the four One-way senescence scores (**I-J**) split into G1 (**G, I**) and non-G1 (S,  
1198 G2, and M) (**H, J**) MuSCs and progenitors. (**K**) Table of the area under the curve (AUC) for each  
1199 ROC curve. (**L-M**) Venn diagrams of the unique and shared up-regulated genes found in the Two-  
1200 way senescence scores (**L**) and the One-way senescence scores (**M**).




1201 **Supplemental Figure 8: Identified two doublet clusters in the myogenic subset that were**  
 1202 **not identified by DoubletFinder. (A-B) Scatter plots of the log-normalized expression levels of**  
 1203 ***Pax7* and *Pecam1* (A) and *Acta1* and *C1qa* (B) by broad myogenic IDs as defined in Figure 4A.**  
 1204 **A density curve is plotted on each axis.**




1205 **Supplemental Figure 9: Identifying a transitional myonuclei state.** (A-C) Same UMAP of the  
 1206 myogenic subset as in **Figure 4A** colored by broad myogenic IDs (A) and colored by the log-  
 1207 normalized expression of *Myh1* (B) and *Myh4* (C). (D-F) Scatter plots of the log-normalized  
 1208 expression levels of *Myh1* and *Myh4* in the myonuclei clusters Type IIx (D), Type IIb (E), and Type  
 1209 IIx/IIb (F). The dotted-line boxes highlight the cells that express the marker(s) that should be  
 1210 expressed in each myonuclei cluster. (G) Stacked bar plot of the fraction of cells within each  
 1211 myonuclei cluster that express a combination of *Myh1* and *Myh4*. (H) Violin plots of the log-  
 1212 normalized expression levels of markers of high metabolic rate (*Tnnc2*, *Tnni2*, *Mb*, *Cox6a2*,  
 1213 *Cox6c*, *Atp5e*, *Atp5g1*) and myonuclei (*Ckm*, *Myh2*, *Myh1*, *Myh4*, *Chrne*, *Col22a1*) in each  
 1214 myonuclei cluster. (I) Violin plot of the percent of mitochondrial reads in each myonuclei cluster.





1216 **Supplemental Figure 10: Myogenic subset pseudotime analysis. (A-H)** Dot Plots of the  
1217 average log-normalized expression of *Pax7* (A), *Myf5* (B), *Myod1* (C), *Myog* (D), *Mymk* (E), *Acta1*  
1218 (F), *Cdk1* (G), and *Cdk4* (H) in each day post injury (dpi) and pseudotime bin. The size of the  
1219 circle is the percent of cells in each pseudotime bin for each age and dpi combination. (I)  
1220 Schematic of newly assigned myogenic IDs (referred to as 'pseudotime-based myogenic cell state  
1221 bin') based on the expression of known myogenic markers in each dpi and pseudotime bin.



1223 **Supplemental Figure 11: Cell cycle workflow.** (A-C) The polar coordinates in **Figure 4D** were  
1224 converted to cartesian coordinates (A) and rescaled to fit in a range from 0 to 1 (this plot is the  
1225 same as in **Figure 4E**) (B). The cells are colored by the predicted cell cycle phase based on the  
1226 two scores (A-B) and G1 status (C). (D) Distribution of MuSCs and progenitors across the  
1227 normalized theta values. The black line represents the standard Seurat G1 cutoff (normalized  
1228 theta = 0.25), and the red line represents our extended G1 cutoff (normalized theta = 0.375). (E)  
1229 Violin plot of the distribution of the normalized theta values in MuSCs and progenitors split by age  
1230 and days post injury (dpi). (F) Violin plot of the distribution of the normalized theta values in  
1231 MuSCs and progenitors split by pseudotime bin. (G-H) Scatter plot of the normalized theta values  
1232 and the One-way FBR senescence score in MuSCs and progenitors. The cells are colored by log-  
1233 normalized *Cdkn2a* expression (G) and by *Cdkn1a* expression (H). The vertical line is the  
1234 extended G1 cutoff, and the horizontal line is where 50% of the cells above this line co-express  
1235 *Cdkn2a* and *Cdkn1a*.

A

Cell Types	0	1	2	3.5	5	7 dpi
Endo cells (3 CTs)	49.2	16.8	8.9	4.7	7.2	17.6
FAPs (3 CTs)	20.4	10.7	7.2	9.3	15.2	25.3
Immune cells (17 CTs)	2.7	60.9	79.7	75.2	63.2	32.1
MuSCs + Prog	2.0	2.1	1.1	8.1	9.7	7.5
Myonuclei	15.1	3.3	0.9	1.5	2.5	10.6
Pericytes/SM	4.6	2.5	1.2	0.6	1.3	3.3
Neural	3.4	1.1	0.5	0.3	0.4	1.5
Tenocytes	2.6	2.5	0.5	0.3	0.5	2.1

B

Cell Types	% of Total Cells					
	0	1	2	3.5	5	7 dpi
Endo cells (Artery)	5.7	1.2	0.8	0.4	0.6	1.8
Endo cells (Capillary)	42.4	15.2	7.9	4.2	6.2	15.1
Endo cells (Vein)	1.1	0.4	0.2	0.2	0.3	0.7
FAPs (Adipogenic)	15.6	7.9	4.4	7.3	12.8	21.4
FAPs (Pro-remodeling)	0.0	1.8	2.2	1.3	1.3	0.2
FAPs (Stem)	4.8	1.0	0.7	0.6	1.2	3.8
Immune cells (17 CTs)	2.7	60.9	79.7	75.2	63.2	32.1
MuSCs + Prog	2.0	2.1	1.1	8.1	9.7	7.5
Myonuclei	15.1	3.3	0.9	1.5	2.5	10.6
Pericytes/SM	4.6	2.5	1.2	0.6	1.3	3.3
Neural	3.4	1.1	0.5	0.3	0.4	1.5
Tenocytes	2.6	2.5	0.5	0.3	0.5	2.1

C

Cell Types	% of Immune Cells					
	0	1	2	3.5	5	7 dpi
B cells	14.6	0.6	0.4	0.3	0.5	4.6
Dendritic cells (4 CTs)	13.9	5.6	6.8	6.5	9.9	9.2
Endo/Myeloid	0.5	0.7	0.1	0.0	0.0	0.0
Mono/Macro (Cycling)	5.3	0.8	4.1	8.4	2.9	2.6
Mono/Macro ( <i>Cxcl10</i> +)	0.3	4.0	5.9	6.8	4.7	5.0
Mono/Macro (Patrolling)	0.0	13.7	24.9	25.7	20.3	13.2
Mono/Macro ( <i>Ccr2</i> +)	10.8	19.7	15.4	8.0	6.2	4.0
Mono/Macro ( <i>Mrc1</i> +)	16.3	7.8	8.1	9.3	9.5	10.2
Mono/Macro ( <i>Cx3cr1</i> +)	14.5	12.6	21.7	26.9	28.7	24.1
Neutrophils	9.3	32.0	9.7	2.4	2.4	2.9
NK cells	2.3	0.6	0.8	1.7	4.5	4.3
T cells (3 CTs)	12.5	1.9	2.1	3.9	10.3	20.0

D

Cell Types	% of Immune Cells					
	0	1	2	3.5	5	7 dpi
B cells	14.6	0.6	0.4	0.3	0.5	4.6
DC ( <i>Cd209a</i> +)	10.6	4.3	5.2	4.5	5.8	5.1
DC ( <i>Cd72</i> +)	1.1	0.4	0.2	0.4	0.4	0.6
DC ( <i>Fscn1</i> +)	0.0	0.3	0.3	0.6	1.5	1.5
DC ( <i>Xcr1</i> +)	2.1	0.7	1.1	1.1	2.2	2.1
Endo/Myeloid	0.5	0.7	0.1	0.0	0.0	0.0
Mono/Macro (Cycling)	5.3	0.8	4.1	8.4	2.9	2.6
Mono/Macro ( <i>Cxcl10</i> +)	0.3	4.0	5.9	6.8	4.7	5.0
Mono/Macro (Patrolling)	0.0	13.7	24.9	25.7	20.3	13.2
Mono/Macro ( <i>Ccr2</i> +)	10.8	19.7	15.4	8.0	6.2	4.0
Mono/Macro ( <i>Mrc1</i> +)	16.3	7.8	8.1	9.3	9.5	10.2
Mono/Macro ( <i>Cx3cr1</i> +)	14.5	12.6	21.7	26.9	28.7	24.1
Neutrophils	9.3	32.0	9.7	2.4	2.4	2.9
NK cells	2.3	0.6	0.8	1.7	4.5	4.3
T cells ( <i>Cd4</i> +)	0.3	0.2	0.4	0.5	0.7	1.0
T cells (Cycling)	0.6	0.0	0.1	0.3	0.6	1.1
T cells (Non-cycling)	11.6	1.7	1.6	3.1	9.0	17.8

1237 **Supplementary Table 1: Determining the cell type composition in each day post injury. (A-**  
1238 **B)** Percent of each cell type found at a given day post injury (dpi). The three endothelial  
1239 populations were combined into “Endo (3 CTs)”, the three FAPs populations were combined into  
1240 “FAPs (3 CTs)”, and the 17 immune populations were combined into “Immune cells (17 CTs)” **(A)**.  
1241 Only the 17 immune populations are combined into “Immune cells (17 CTs)” **(B)**. **(C-D)** Percent  
1242 of each immune cell type out of all immune cells at a given dpi. The four dendritic cell populations  
1243 were combined into “Dendritic cells (4 CTs)” and the three T cell populations were combined into  
1244 “T cells (3 CTs)” **(C)**. All individual immune cell type IDs **(D)**.

Cell Type	Equation used in non-linear modeling	p-value	FDR-corrected p-value
B cells	Quadratic	1.45E-03	4.06E-02
Dendritic cells ( <i>Cd209a+</i> )	Quadratic	4.65E-02	1.00E+00
Dendritic cells ( <i>Cd72+</i> )	Quadratic	3.60E-01	1.00E+00
Dendritic cells ( <i>Xcr1+</i> )	Quadratic	2.02E-01	1.00E+00
Endothelial and Myeloid cells	Quadratic	7.66E-01	1.00E+00
Endothelial cells (Capillary)	Quadratic	7.27E-01	1.00E+00
FAPs (Adipogenic)	Quadratic	4.25E-01	1.00E+00
FAPs (Stem)	Quadratic	2.91E-02	8.14E-01
Mono/Macro ( <i>Cxcl10+</i> )	Quadratic	8.30E-01	1.00E+00
Myonuclei	Quadratic	1.76E-01	1.00E+00
Pericytes/SM	Quadratic	2.62E-03	7.32E-02
Schwann and Neural/Glial cells	Quadratic	1.06E-01	1.00E+00
T cells ( <i>Cd4+</i> )	Quadratic	3.36E-01	1.00E+00
T cells (Cycling)	Quadratic	4.37E-01	1.00E+00
T cells (Non-cycling)	Quadratic	7.06E-04	1.98E-02
Tenocytes	Quadratic	3.86E-02	1.00E+00
Dendritic cells ( <i>Fscn1+</i> )	Cubic	5.65E-06	1.58E-04
Endothelial cells (Artery)	Cubic	1.08E-02	3.03E-01
Endothelial cells (Vein)	Cubic	7.71E-01	1.00E+00
FAPs (Pro-remodeling)	Cubic	5.06E-01	1.00E+00
Mono/Macro ( <i>Mrc1+</i> )	Cubic	1.26E-08	3.52E-07
Mono/Macro ( <i>Cx3cr1+</i> )	Cubic	1.92E-04	5.37E-03
MuSCs and progenitors	Cubic	4.10E-02	1.00E+00
NK cells	Cubic	8.17E-08	2.29E-06
Mono/Macro (Cycling)	Quartic	2.66E-05	7.46E-04
Mono/Macro (Patrolling)	Quartic	6.71E-06	1.88E-04
Mono/Macro ( <i>Ccr2+</i> )	Quartic	1.00E-02	2.81E-01
Neutrophils	Quartic	9.47E-02	1.00E+00

1245 **Supplementary Table 2: Cell type dynamics statistics summary.** For all cell types, listed the  
1246 equation type used in the non-linear modeling, the unadjusted p-value, and the FDR adjusted p-  
1247 value. The adjusted p-values that are significant (<0.05) are in red.

1248 **EXTENDED DATA FILES**

1249

1250 **Extended Data File 1: Summary of single-cell RNA-sequencing samples in this study.**

1251

1252 **Extended Data File 2: Lists of senescence gene signatures used in this study.**